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A B S T R A C T
Background
Breech presentation is associated with increased complications. Turning a breech baby to head first presentation using external cephalic
version (ECV) attempts to reduce the chances of breech presentation at birth so as to avoid the adverse effects of breech vaginal birth
or caesarean section. Interventions such as tocolytic drugs and other methods have been used in an attempt to facilitate ECV.
Objectives
To assess, from the best evidence available, the effects of interventions such as tocolysis, acoustic stimulation for midline spine position,
regional analgesia (epidural or spinal), transabdominal amnioinfusion, systemic opioids and hypnosis, or the use of abdominal lubricants,
on ECV at term for successful version, presentation at birth, method of birth and perinatal and maternal morbidity and mortality.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 September 2014) and the reference lists of identified
studies.
Selection criteria
Randomised and quasi-randomised trials comparing the above interventions with no intervention or other methods to facilitate ECV
at term.
Data collection and analysis
We assessed eligibility and trial quality. Two review authors independently assessed for inclusion all potential studies identified as a
result of the search strategy and independently extracted the data using a specially designed data extraction form.
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Main results
We included 28 studies, providing data on 2786 women. We used the random-effects model for pooling data because of clinical
heterogeneity between studies. A number of trial reports gave insufficient information to allow clear assessment of risk of bias. We used
GradePro software to carry out formal assessments of quality of the evidence for beta stimulants versus placebo and regional analgesia
with tocolysis versus tocolysis alone.
Tocolytic parenteral beta stimulants were effective in increasing cephalic presentations in labour (average risk ratio (RR) 1.68, 95%
confidence interval (CI) 1.14 to 2.48, five studies, 459 women, low-quality evidence) and in reducing the number of caesarean sections
(average RR 0.77, 95% CI 0.67 to 0.88, six studies, 742 women, moderate-quality evidence). Failure to achieve a cephalic vaginal
birth was less likely for women receiving a parenteral beta stimulant (average RR 0.75, 95% CI 0.60 to 0.92, four studies, 399 women,
moderate-quality evidence). No clear differences in fetal bradycardias were identified, although this was reported for only one study,
which was underpowered for assessing this outcome. Failed external cephalic version was reported in nine studies (900 women), and
women receiving parenteral beta stimulants were less likely to have failure compared with controls (average RR 0.70, 95% CI 0.60 to
0.82, moderate-quality evidence). Perinatal mortality and serious morbidity were not reported. Sensitivity analysis by study quality was
consistent with overall findings.
For other classes of tocolytic drugs (calcium channel blockers and nitric oxide donors), evidence was insufficient to permit conclusions;
outcomes were reported for only one or two studies, which were underpowered to demonstrate differences between treatment and
control groups. Little evidence was found regarding adverse effects, although nitric oxide donors were associated with increased risk of
headache. Data comparing different tocolytic drugs were insufficient.
Regional analgesia in combination with a tocolytic was more effective than the tocolytic alone for increasing successful versions (assessed
by the rate of failed ECVs; average RR 0.61, 95% CI 0.43 to 0.86, five studies, 409 women, moderate-quality evidence), and no
difference was identified in cephalic presentation in labour (average RR 1.44, 95% CI 0.78 to 2.66, three studies, 279 women, very
low-quality evidence), caesarean sections (average RR 0.74, 95% CI 0.40 to 1.37, three studies, 279 women, very low-quality evidence)
nor fetal bradycardia (average RR 1.48, 95% CI 0.62 to 3.57, two studies, 210 women, low-quality evidence), although studies were
underpowered for assessing these outcomes. Studies did not report on failure to achieve a cephalic vaginal birth (breech vaginal deliveries
plus caesarean sections) nor on perinatal mortality or serious infant morbidity.
Data were insufficient on the use of regional analgesia without tocolysis, vibroacoustic stimulation, amnioinfusion, systemic opioids
and hypnosis, and on the use of talcum powder or gel to assist external cephalic version, to permit conclusions about their effectiveness
and safety.
Authors’ conclusions
Parenteral beta stimulants were effective in facilitating successful ECV, increasing cephalic presentation in labour and reducing the
caesarean section rate, but data on adverse effects were insufficient. Data on calcium channel blockers and nitric acid donors were
insufficient to provide good evidence.
The scope for further research is clear. Possible benefits of tocolysis in reducing the force required for successful version and possible
risks of side effects need to be addressed further. Further trials are needed to compare the effectiveness of routine versus selective use
of tocolysis and the role of regional analgesia, fetal acoustic stimulation, amnioinfusion and abdominal lubricants, and the effects
of hypnosis, in facilitating ECV. Although randomised trials of nitric oxide donors are small, the results are sufficiently negative to
discourage further trials. Intervention fidelity for ECV can be enhanced by standardisation of the techniques and processes used for
clinical manipulation of the fetus in the abdominal cavity and ought to be the subject of further research.
P L A I N L A N G U A G E S U M M A R Y
Ways to help turn a breech baby to head first presentation at the end of pregnancy
Babies born in the breech position (bottom first) are at increased risk of complications at birth because of a delay in birth of the head.
Turning a breech baby to head first in late pregnancy may reduce these complications. A procedure called ’external cephalic version
(ECV)’ describes when practitioners use their hands on the woman’s abdomen to gently try to turn the baby from the breech position
to head first. A number of treatments may help the success of ECV. These include using tocolytic drugs (drugs like beta stimulants and
calcium channel blockers that relax the womb), stimulating the baby with sound through the mother’s abdomen (acoustic stimulation),
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increasing the fluid surrounding the baby (transabdominal amnioinfusion), injecting pain-relieving drugs into the mother’s lower back
to produce regional analgesia (epidural or spinal analgesia), giving the mother opioid drugs to help her relax, using hypnosis and
applying gel or talcum powder to the mother’s abdomen.
This review of trials found 28 randomised controlled studies involving 2786 women. Most studies looked at the effects of tocolytic
beta stimulant drugs. Results showed that babies are more likely to turn head first during ECV and to remain head first for the start of
labour, if women receive beta stimulants. These drugs also reduced the number of caesarean sections, but insufficient data on possible
adverse effects were collected. Little information on other types of tocolytic drugs was available, although nitric oxide donors were
associated with an increase in headaches. In addition, too little evidence was available to show whether the other ways of trying to help
ECV are effective. Further research is needed if we are to increase the success of ECV.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Beta stimulant compared with placebo for helping to turn babies with breech presentation when ECV was used
Patient or population: pat ients with breech presentat ion
Settings: studies in hospital sett ings
Intervention: beta st imulant
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Beta stimulant
Cephalic presentation
at birth (primary)
Study population RR 1.68
(1.14 to 2.48)
459
(5 studies)
⊕⊕©©
Low1,2
294 per 1000 494 per 1000
(335 to 729)
Moderate
255 per 1000 428 per 1000
(291 to 632)
Cephalic vaginal birth
not achieved (CS +
breech vaginal birth)
primary outcome
Study population RR 0.75
(0.6 to 0.92)
399
(4 studies)
⊕⊕⊕©
Moderate3
727 per 1000 545 per 1000
(436 to 669)
Moderate
708 per 1000 531 per 1000
(425 to 651)
Caesarean section
(primary)
Study population RR 0.77
(0.67 to 0.88)
742
(6 studies)
⊕⊕⊕©
Moderate1
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670 per 1000 516 per 1000
(449 to 590)
Moderate
707 per 1000 544 per 1000
(474 to 622)
Fetal bradycardia (pri-
mary)
Study population RR 2.81
(0.12 to 66.17)
58
(1 study)
⊕©©©
Very low4,5
0 per 1000 0 per 1000
(0 to 0)
Moderate
0 per 1000 0 per 1000
(0 to 0)
Failed external
cephalic version
Study population RR 0.7
(0.6 to 0.82)
900
(9 studies)
⊕⊕⊕©
Moderate1
654 per 1000 458 per 1000
(393 to 537)
Moderate
632 per 1000 442 per 1000
(379 to 518)
Perinatal mortality See comment See comment Not est imable 0
(0)
See comment No data reported
Perinatal morbidity See comment See comment Not est imable 0
(0)
See comment No data reported
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io.
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. Most studies contribut ing data had design lim itat ions.
2. I2 > 60%. Ef fect size varied considerably.
3. All studies providing data had design lim itat ions.
4. The one study included is of poor quality, as it is an unblinded quasi-RCT.
5. Wide 95% CI crossing the line of no ef fect; small sample size and low event rate.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Breech presentation occurs when the baby is positioned bottom
first. It is more common in early pregnancy, and the incidence
decreases with increasing gestational age. The incidence at term
is about 3% to 4% (Hickok 1992). Breech presentation may be
caused by an underlying fetal or maternal abnormality, it may be
an apparently chance occurrence or it may be related to an other-
wise benign variant such as cornual placental position (the placenta
situated in an upper lateral corner of the uterus). In the latter two
instances, breech presentation places a healthy baby and mother
at increased risk of a complicated vaginal birth or caesarean sec-
tion. Therefore, it is understandable that obstetricians, midwives
and consumer groups take considerable interest in this topic. Pre-
vention of harm with reduction of risk for mother and baby is a
quantifiable outcome of carefully gathering this research evidence.
Knowing what works best for whom and in what circumstances is
the concern of clinical researchers working in this field.
Considerable disagreement surrounds the management of breech
(bottom first) presentation, with respect to both the place of exter-
nal cephalic version (ECV) and the type of birth. Interpretation
of the findings of non-randomised trials is confounded by the fact
that breech presentationper se appears to be amarker for poor peri-
natal outcome. For example, the incidence of childhood handicap
following breech presentation has been found to be high (16%)
for both babies born vaginally and those born by caesarean section
(Danielian 1996). Randomised trials of planned mode of birth for
vaginal breech birth have shown short-term benefit for the breech
presenting baby managed by planned caesarean section compared
with planned vaginal birth, although the impact on future preg-
nancies remains uncertain (Hofmeyr 2003). Two-year outcomes
of one of these randomised trials showed no significant difference
in the combined risk of death/neurodevelopmental delay between
planned vaginal and planned caesarean groups (Whyte 2004). De-
spite this, these results have had a profound effect on clinical prac-
tice, and inmany institutions, caesarean section for breech presen-
tation has become routine. Under these circumstances, the impact
of ECV on caesarean section rates would be expected to be greater
than was the case in previous trials in institutions in which vaginal
breech birth was common. The increased rate of caesarean section
for breech presentation has decreased the rate of vaginal breech
births, and concern has arisen that practitioners are losing the skill
of supporting women who have vaginal breech births.
Breech presentation can be classified as complete, frank or incom-
plete. A complete breech occurs when the baby’s hips and knees are
flexed, with feet near the buttocks. A frank breech presentation is
seen when the baby’s legs are extended up to its head. Incomplete
breech presentations include a footling breech, in which one or
both legs are extended below the baby’s bottom, and a kneeling
breech, whereby the knees are the presenting part of the breech.
Although underlying reasons may explain the breech presentation,
the baby may have a more difficult vaginal birth because of the
delay in birth of the head.
Description of the intervention
External cephalic version
During an ECV, practitioners use their hands on the woman’s
abdomen to gently try to turn the baby from the breech position to
the head-down position. A video of the procedure can be viewed
at https://www.youtube.com/watch?v=fKaNZfUno50.
External cephalic version before term became a part of routine ob-
stetrical practice on the basis of the self-evident immediate effec-
tiveness of the procedure, as well as reassuring results from several
non-randomised trials, and in spite of the negative results of the
only randomised trial reported before 1980 (Brosset 1956). The
popularity of ECV before termwaned after the mid-1970s, in part
because of reports of an increase in perinatal mortality associated
with the procedure (Bradley-Watson 1975), which, in retrospect,
may have been due to application of undue force and the increas-
ing perception of caesarean section as a safer option than ECV or
breech birth.
Before the mid-1970s, ECV was usually attempted before term
because of the belief that the procedure would seldombe successful
at term. Subsequent studies showed that with the use of tocolysis,
ECV could be achieved in a substantial proportion of women
with breech presentation at term (37 or more completed weeks
of pregnancy). Predictors of unsuccessful version include engaged
presenting part, fetal head not easily palpable and tense uterus
(Lau 1997).
Initially, successful ECV at a late stage of pregnancywas considered
to have become possible only because of the use of tocolytic drugs
to relax the uterus. However, later studies showed that ECV at
term was frequently possible without tocolysis. The overall success
rate was 60% in a systematic review of randomised controlled
trials in which some trials included facilitation and others did not
(Hofmeyr 1996).
The question, therefore, arose as to whether tocolysis should be
used routinely for ECV at term, or only in those cases in which
difficulty is anticipated or initial attempts fail.
A number of interventions to try to make ECV easier and more
successful have been suggested, including use of tocolytic drugs,
vibroacoustic stimulation, regional analgesia, amnioinfusion, ma-
ternal hydration, systemic opioid drugs, hypnosis and abdominal
lubricants.
How the intervention might work
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Tocolysis to facilitate ECV at term
1. Beta stimulants, such as salbutamol, ritodrine,
hexoprenaline or terbutaline, are widely used tocolytics. They are
usually given intravenously. Possible side effects for mother and
baby include tachycardia (increase in heart rate).
2. Calcium channel blockers, like nifedipine, can be
administered orally (Smith 2000). These drugs can be associated
with hypotension (fall in blood pressure).
3. Nitric oxide donors, such as intravenous nitroglycerine
(Belfort 1993) or sublingual glyceryl trinitrate/nitroglycerine
spray (Reddick 1997; Yanny 2000), have been suggested as
alternative tocolytics.
Vibroacoustic stimulation to facilitate ECV at term
This procedure is performed when the baby is stimulated using
sound applied to the mother’s abdomen to provoke the baby to
move out of the midline position. It has been studied in one small
trial, which is included in this review (Johnson 1995).
Regional analgesia to facilitate ECV at term
Regional analgesia includes spinal and epidural anaesthesia. Epidu-
ral analgesia is provided when an anaesthetic drug is infused into
the epidural space. Spinal analgesia is given when an anaesthetic
drug is injected into the cerebrospinal fluid. In a retrospective
cohort study, ECV at term was successful in 59% of 32 women
with epidural analgesia, and in 24% of 37 women without (Carlan
1994). In an uncontrolled study, ECV under epidural analgesia
was successful in nine of 16 women (56%) in whom initial at-
tempts had failed (Neiger 1998a; Neiger 1998b). Common ad-
verse effects of these analgesics include hypotension and headache.
Amnioinfusion to facilitate ECV at term
An amnioinfusion is a procedure whereby saline is infused into the
amniotic sac to increase the volume of fluid to enable the baby to
turn more easily. Amnioinfusions can be done transabdominally
or transvaginally. In an uncontrolled study, six women with failed
ECV had a successful repeat attempt following transabdominal
amnioinfusion with 700 mL to 900 mL warmed saline (Benifla
1995). To our knowledge, no randomised trials have determined
the effectiveness of this intervention.
Systemic opioids to facilitate ECV at term
Systemic opioids may facilitate ECV by relaxing the mother and
reducing her sense of discomfort during the procedure.
Hypnosis to facilitate ECV at term
Different types of hypnosis may facilitate ECV by promoting re-
laxation, thereby potentially reducing the woman’s sense of dis-
comfort during the procedure.
Talcum powder and gel to facilitate ECV at term
Powder or gel applied to the woman’s abdomen may act as a lu-
bricant, possibly allowing smoother hand movements during at-
tempts to turn the baby.
Why it is important to do this review
It is important to assess whether various interventions do increase
the effectiveness of ECV in turning a breech baby to head first
presentation and to help guide their use in clinical practice. Many
of these interventions are commonly used, and it is important
for doctors to be able to apply evidence-based medicine in this
setting to offer the mother the greatest chance of success when
undergoing an ECV. It must also be determined whether any of
these interventions is associated with possible harm to mother or
fetus.
Readers are referred to previous reviews of the topic (Hofmeyr
1989; Hofmeyr 1991; Hofmeyr 1992; Hofmeyr 1993; Hofmeyr
2014; Zhang 1993) - see also related Cochrane reviews: ’Cephalic
version by postural management for breech presentation’ (
Hofmeyr 2012b); ’Cephalic version by moxibustion for breech
presentation’ (Coyle 2012); ’External cephalic version for breech
presentation at term’ (Hofmeyr 2012a); and ’External cephalic
version for breech presentation before term’ (Hutton 2006).
O B J E C T I V E S
To assess, from the best evidence available, the effects of interven-
tions such as tocolysis, acoustic stimulation for midline spine po-
sition, regional analgesia (epidural or spinal), transabdominal am-
nioinfusion, systemic opioids and hypnosis, or the use of abdomi-
nal lubricants, on ECV at term for successful version, presentation
at birth, method of birth and perinatal and maternal morbidity
and mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Clinical trials comparing the effects of interventions such as rou-
tine tocolysis versus selective or no use of tocolysis, or different
tocolytics, epidural or spinal analgesia, amnioinfusion, maternal
hydration, systemic opioids and fetal acoustic stimulation in mid-
line fetal spine positions or hypnosis or abdominal lubricants on
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clinically meaningful outcomes, with random or quasi-random al-
location to treatment and control groups and with violations of al-
located management and exclusions after allocation not sufficient
to materially affect outcomes.
Types of participants
Women with singleton breech presentations at term and no con-
traindications to ECV or the intervention being studied, with or
without previous failed ECV.
Types of interventions
A. Tocolytic drugs.
B. Vibroacoustic stimulation in midline fetal spine positions.
C. Regional analgesia.
D. Amnioinfusion.
E. Systemic opioids.
To avoid duplication of data, we have listed the interventions un-
der study in order, from A to E. Each intervention will be com-
pared with placebo and with only those interventions above it on
the list. Thus, the intervention ’Regional analgesia’ (C) will be
compared with placebo, then with tocolytic drugs (A), then with
vibroacoustic stimulation (B) and finally with other regional anal-
gesia (C). When C is compared with C, different types of regional
analgesia are compared with each other, so epidural may be com-
pared with spinal analgesia as an intervention to facilitate ECV.
Interventions identified in the future will be added to the end of
the list.
In this update we identified trials examining other types of inter-
ventions used to facilitate ECV.
F. Hypnosis*.
G. Abdominal lubricants* (talcum powder versus gel).
*We decided to include these interventions, although they were
not prespecified in the original protocol.
Types of outcome measures
Primary outcomes
1. Cephalic presentation at labour and at birth.
2. Failure to achieve cephalic vaginal birth (composite
outcome: caesarean section plus vaginal breech birth)*.
3. Caesarean section.
4. Fetal bradycardia or prolonged decelerations as defined by
trial authors.
Secondary outcomes
1. Failed external cephalic version.
2. Difficult external cephalic version.
3. Maternal palpitations.
4. Maternal headaches.
5. Maternal hypotension.
6. Operative vaginal birth.
7. Maternal mortality.
8. Maternal morbidity.
9. Perinatal mortality.
10. Perinatal morbidity.
We have included other outcomes, not specified here, when they
were reported in the studies and when we considered them to be
clinically important: vaginal breech birth, Apgar less than seven at
five minutes, neonatal seizures, admission to neonatal unit, birth
trauma, flushing in women, placental abruption, maternal dis-
comfort, pain scores, maternal satisfaction with the procedure and
maternal side effects (nausea and vomiting, dizziness and drowsi-
ness).
*In this version of the review, a new primary outcome has been
added. The purpose of ECV is to avoid breech presentation, which
increases the risk of caesarean section and of breech vaginal deliv-
ery. For this reason, and to increase consistency with other related
Cochrane reviews, we have added a composite outcome “Failure to
achieve cephalic vaginal birth,” which represents caesarean section
plus vaginal breech births.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (30
September 2014).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
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Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For this update, we used the following methods. These methods
are based on a standard template used by the Cochrane Pregnancy
and Childbirth Group.
Selection of studies
Two review authors independently assessed for inclusion all poten-
tial studies identified as a result of the search strategy. We resolved
disagreements through discussion, or, if required, we consulted
the other review authors to achieve consensus.
Data extraction and management
We designed a form on which to record extracted data. For eligible
studies, two review authors extracted data using the agreed upon
form.We resolved discrepancies through discussion, or, if required,
we consulted the third review author. We entered the data into
Review Manager software (RevMan 2014) and checked them for
accuracy.
When information in trial reports was unclear, we planned to
contact report authors to request further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
disagreements by discussion with the other review authors.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
allocation to interventions before assignment and assessedwhether
intervention allocation could have been foreseen in advance of, or
during, recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth); or
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants; and
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the quantity, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total number of randomly assigned
participants), reasons for attrition or exclusion when reported and
whether missing data were balanced across groups or were related
to outcomes. When sufficient information was reported, or could
be supplied by the trial authors, we planned to reinclude missing
data in the analyses that we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
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• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation); or
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed these methods as:
• low risk of bias (when it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (when not all of the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely and so cannot be used; study failed to
include results of a key outcome that would have been expected
to have been reported); or
• unclear risk of bias
(6) Other bias (checking for bias due to problems not
covered by the methods listed above)
We described for each included study any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to criteria given in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). With refer-
ence to the methods listed above, we planned to assess the likely
magnitude and direction of bias and whether we considered it
likely to impact the findings. When sufficient data were available,
we explored the impact of the level of bias by undertaking sensi-
tivity analyses - see Sensitivity analysis.
For this update, we assessed the quality of the evidence using the
GRADE approach (Schunemann 2009) to assess the quality of
the body of evidence related to the following outcomes.
1. Cephalic presentation at labour and at birth.
2. Failure to achieve cephalic vaginal birth.
3. Caesarean section.
4. Fetal bradycardia or prolonged decelerations as defined by
trial authors.
5. Failed external cephalic version.
6. Perinatal mortality.
7. Perinatal morbidity.
We graded the evidence and included ’Summary of findings’ tables
for two comparisons.
1. Tocolytics (parenteral beta stimulants) versus placebo.
2. Regional analgesia with tocolysis versus tocolysis alone.
The GRADE profiler (Grade 2014) was used to import data from
Review Manager 5.3 (RevMan 2014) to create ’Summary of find-
ings’ tables. We produced a summary of the intervention effect
and a measure of quality for each of the above outcomes by using
the GRADE (Grades of Recommendation, Assessment, Develop-
ment and Evaluation) approach. The GRADE approach uses five
considerations (study limitations, consistency of effect, impreci-
sion, indirectness and publication bias) to assess the quality of the
body of evidence for each outcome. Evidence can be downgraded
from ’high quality’ by one level for serious, or by two levels for
very serious, limitations depending on assessments for risk of bias,
indirectness of evidence, serious inconsistency, imprecision of ef-
fect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we have presented results as summary risk
ratios with 95% confidence intervals.
Continuous data
We used mean differences if outcomes were measured in the same
way between trials.We used standardisedmean differences to com-
bine trials that measured the same outcome but used different
methods.
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses
along with individually randomised trials if they were otherwise
eligible. For this version of the review, we identified no such trials;
if they are included in future updates, we will adjust sample sizes
using the methods described in theCochrane Handbook for System-
atic Reviews of Interventions based on an estimate of the intracluster
correlation co-efficient (ICC) derived from the trial (if possible),
from a similar trial or from a study of a similar population. If we
use ICCs from other sources, we will report this and will conduct
sensitivity analyses to investigate the effects of variation in the
ICC. If we identify both cluster-randomised trials and individu-
ally randomised trials, we plan to synthesise relevant information.
We will consider it reasonable to combine the results from both
if little heterogeneity is noted between study designs, and if the
interaction between effects of the intervention and choice of the
randomisation unit is considered unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and will perform a sensitivity analysis to investigate the effects of
the randomisation unit.
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Cross-over trials
We did not plan to include trials with a cross-over design. One
of the trials that was otherwise eligible for inclusion randomly as-
signed women to two groups (parallel design), but if after two at-
tempts the randomised ECV method was not successful, the trial
protocol allowed the alternative method to be used (Vallikkannu
2014). We treated this study as a parallel-group randomised con-
trolled trial and used only data collected before any cross-over to
the alternative method.
Other unit of analysis issues
We excluded trials including multiple pregnancies.
In this version of the review, we did not include trials withmultiple
treatment arms; if we identify such trials for inclusion in future
updates, we will use themethods set out in theCochrane Handbook
for Systematic Reviews of Interventions for analysis.
Dealing with missing data
For included studies, we noted levels of attrition. In future updates,
if more eligible studies are included, review authors will explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis (i.e. we attempted to include in the analy-
ses all participants randomly assigned to each group). The denom-
inator for each outcome in each trial was the number randomly
assigned minus the number of participants whose outcomes were
known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if I² was greater than 30% and either Tau² was greater
than zero or the P value (< 0.10) in the Chi² test for heterogene-
ity was low. If we identified substantial heterogeneity (> 30%),
we planned to explore this by performing prespecified subgroup
analysis.
Assessment of reporting biases
In future updates, if 10 or more studies are included in the meta-
analysis, we plan to investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate this.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used the random-effectsmodel for pool-
ing data because of clinical heterogeneity in the included studies in
various comparisons. The random-effects summary represents the
average range of possible treatment effects, and we have discussed
the clinical implications of differing treatment effects between tri-
als. If the average treatment effect was not considered clinically
meaningful, we did not combine trials. We have presented results
as the average treatment effect with 95% confidence intervals, and
when heterogeneity between trials was noted, with estimates of
Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated this by
using subgroup analyses.
When data were available, we planned to carry out the following
analysis.
1. nulliparous versus multiparous women.
We restricted subgroup analysis to the review’s primary outcomes.
We assessed subgroup differences by performing interaction tests
available within RevMan (RevMan 2014). We reported the results
of subgroup analyses by quoting the Chi² statistic and the P value,
and results of the interaction test by reporting the I² value.
Sensitivity analysis
We explored heterogeneity by performing sensitivity analysis,
looking at primary outcomes only, and by excluding trials with
greater risk of bias. We considered studies at low risk of bias when
they had low risk of bias in generation of the randomisation se-
quence, concealment of allocation and loss to follow-up.
R E S U L T S
Description of studies
Results of the search
In total the search identified 56 reports corresponding to 36 stud-
ies. In the previous published review (Cluver 2012), 25 studies
met the inclusion criteria, and in this update, we have included
three additional trials (Munoz 2014; Reinhard 2012; Vallikkannu
2014). The 28 included studies involved a total of 2786 women.
We have set out information about all of the included trials in the
Characteristics of included studies tables.
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Included studies
We found 17 studies involving 1876 women that assessed to-
colytic drugs (Bujold 2003a; Bujold 2003b; Chung 1996; Collaris
2009; El-Sayed 2004; Fernandez 1997;Hilton 2009; Impey 2005;
Kok 2008; Marquette 1996; Nor Azlin 2005; Nor Azlin 2008;
Robertson 1987; Stock 1993; Tan 1989; Vani 2009; Yanny 2000).
These drugs included beta stimulants (salbutamol, ritodrine, hex-
oprenaline and terbutaline), a calcium channel blocker (nifedip-
ine) and a nitric oxide donor (nitroglycerine/glyceryl trinitrate).
We found one study involving 26 women that assessed vibroa-
coustic stimulation (Johnson 1995).
We found six studies involving 554 women that assessed regional
analgesia (Delisle 2001; Dugoff 1999; Mancuso 2000; Schorr
1997; Weiniger 2007; Weiniger 2010). Five of these studies used
a tocolytic drug as well in both groups (Dugoff 1999; Mancuso
2000; Schorr 1997; Weiniger 2007; Weiniger 2010), and one
study allowed doctors to use a tocolytic at their discretion (Delisle
2001). None of the studies looked at regional analgesia alone.
We found no studies on amnioinfusion.
We found one study involving 95 women that compared regional
analgesia with systemic opioids, with both groups also receiving a
tocolytic drug (Sullivan 2009).
One study with 60 women examined a systemic opioid (remifen-
tanil) compared with placebo (Munoz 2014).
One study involving 80 women compared two types of hypno-
sis/relaxation (Reinhard 2012), and one (with 95 women) looked
at the application of talcum powder versus gel to assist ECV
(Vallikkannu 2014). In this final study after two failed attempts
at ECV, cross-over to the other method occurred, and although
analysis was done by intention-to-treat (according to original al-
location), a proportion of women in both groups received both
methods, making interpretation of results difficult; for this reason
we have included in the review only data related to the period
before the cross-over.
Three studies are awaiting classification (Andarsio 2000; Hollard
2003; Tan 2008) - see Characteristics of studies awaiting
classification - and two are ongoing (Burgos 2012; Passerini 2013)
- see Characteristics of ongoing studies.
Excluded studies
Weexcluded three studies (Dockeray 1984;Guittier 2013;Wallace
1984) - see Characteristics of excluded studies.
Risk of bias in included studies
See the table of Characteristics of included studies and Figure 1.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We judged 16 studies to be at low risk of bias for both adequate
sequence generation and adequate allocation concealment (Bujold
2003a; Bujold 2003b; Collaris 2009; El-Sayed 2004;Hilton 2009;
Impey 2005; Johnson 1995; Kok 2008; Mancuso 2000; Munoz
2014; Nor Azlin 2005; Nor Azlin 2008; Schorr 1997; Sullivan
2009; Vani 2009; Yanny 2000). We considered one study to be
at high risk of bias for both sequence generation and allocation
concealment (Robertson 1987). The remaining studies were un-
clear, or we observed a mixture of low, high and unclear risk of
bias (Figure 1).
Blinding
We judged 11 studies to be adequately blinded with low risk of
bias for both performance bias (women and staff blinded) and
detection bias (outcome assessors blinded) (Bujold 2003a; Bujold
2003b; Fernandez 1997; Hilton 2009; Kok 2008; Marquette
1996; Munoz 2014; Nor Azlin 2005; Reinhard 2012; Stock
1993; Tan 1989). Eight studies were at high risk of bias for
both performance and detection bias (Mancuso 2000; Robertson
1987; Schorr 1997; Sullivan 2009; Vallikkannu 2014; Vani 2009;
Weiniger 2007;Weiniger 2010). For the remaining studies, blind-
ing was not clearly reported or performance or detection bias was
noted (Figure 1).
Incomplete outcome data
We considered 26 studies at low risk of bias when considering
attrition. In one study, risk of bias was unclear for this domain
(Delisle 2001), and in another study, loss to follow-up meant that
for some outcomes the study was at high risk of bias (Nor Azlin
2008) (Figure 1).
Selective reporting
We classified all but one of the studies as unclear because we did
not assess the trial protocols (Figure 1).
Other potential sources of bias
We considered 14 studies at low risk of bias in terms of other
potential sources of bias, and three at high risk. The remaining
studies were unclear on this (Figure 1).
Effects of interventions
See: Summary of findings for the main comparison Beta
stimulant compared with placebo for helping to turn babies with
breech presentation when ECV was used; Summary of findings
2 Regional analgesia (with tocolysis) versus no intervention
of regional analgesia (with or without tocolysis) for breech
presentation
We included 28 studies, involving 2786 women (Characteristics
of included studies).
Comparison 1. Tocolysis versus placebo for external
cephalic version (ECV) at term (13 studies with
15,468 women)
Thirteen studies involving 1548 women looked at this compar-
ison using various tocolytic drugs (Bujold 2003a; Chung 1996;
Fernandez 1997;Hilton 2009; Impey 2005; Kok 2008;Marquette
1996; Nor Azlin 2005; Robertson 1987; Stock 1993; Tan 1989;
Vani 2009; Yanny 2000).
Beta stimulants:Nine studies looked at beta stimulants. Six stud-
ies involving 639 women looked at parenteral ritodrine (Chung
1996; Impey 2005; Marquette 1996; Nor Azlin 2005; Robertson
1987; Stock 1993); two studies involving 174 women looked
at oral and parenteral salbutamol (Tan 1989; Vani 2009); and
one study involving 103 women looked at parenteral terbutaline
(Fernandez 1997).
Calcium channel blockers: One study involving 320 women
looked at oral nifedipine (Kok 2008).
Nitric oxide donors: Three studies involving 282 women looked
at parenteral or sublingual nitroglycerine/glyceryl nitrate (Bujold
2003a; Hilton 2009; Yanny 2000).
The overall quality of the studies was reasonable. We judged seven
studies to have low risk of bias for both sequence generation and
allocation concealment (Bujold 2003a; Hilton 2009; Impey 2005;
Kok 2008; Nor Azlin 2005; Vani 2009; Yanny 2000) and eight
studies to have adequate blinding (Bujold 2003a; Fernandez 1997;
Hilton 2009; Kok 2008; Marquette 1996; Nor Azlin 2005; Stock
1993; Tan 1989). See Figure 1.
We have used random-effects models throughout these compar-
isons because of the clinical heterogeneity observed between stud-
ies. We have presented data for different classes of tocolytics to-
gether in the same forest plots, but we have not pooled results.
Findings for different classes of tocolytic drugs are also reported
separately in the text, as different classes of drugs have different
mechanisms of action. For most outcomes, evidencemainly relates
to beta stimulants.
Primary outcomes
We found a statistically significant increase in cephalic presenta-
tion at labour and at birth with the use of parenteral beta stimu-
lants (average risk ratio (RR) 1.68, 95% confidence interval (CI)
1.14 to 2.48, five studies, 459 women, random-effects Tau² =
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0.12, I² = 64%, Chi² P value 0.03, evidence graded as low quality;
Analysis 1.1). Relatively little evidence was found for other classes
of tocolytic drugs. One study with 310 women examined the use
of a calcium channel blocker and did not demonstrate a difference
between intervention and control groups for cephalic presentation
at birth (RR 1.13, 95% CI 0.87 to 1.48); single studies examining
parenteral and sublingual nitric oxide donors also showed no sta-
tistically significant differences between intervention and control
groups (RR 1.58, 95% CI 0.91 to 2.76, participants = 125, and,
RR 0.74, 95% CI 0.52 to 1.05, participants = 99, respectively).
Failure to achieve a cephalic vaginal birth was less likely for women
receiving a beta stimulant (average RR 0.75, 95% CI 0.60 to 0.92,
four studies, 399 women, evidence graded as moderate quality;
Analysis 1.2). One study examined the use of a sublingual nitric
oxide donor and reported no clear evidence of differences between
groups (RR 1.22, 95% CI 0.86 to 1.72, participants = 99).
We noted a significant reduction in caesarean sections with the use
of beta stimulants to facilitate ECV (average RR 0.77, 95% CI
0.67 to 0.88, participants = 742, six studies, I² = 25%; Analysis
1.3). Evidence on the impact of calcium channel blockers and
parenteral nitric oxide donors was limited and showed no clear
difference in the rates of caesarean section between treatment and
control groups (calciumchannel blocker: RR1.11, 95%CI0.88 to
1.40, one study, participants = 310; parenteral nitric oxide donor:
RR 0.83, 95% CI 0.67 to 1.02, one study, participants = 125).
We identified no significant difference in fetal bradycardia in any
of the studies reporting this outcome (beta stimulants: RR 2.81,
95% CI 0.12 to 66.17, participants = 58, one study, evidence
graded as very low quality; calcium channel blocker: RR 1.11,
95% CI 0.50 to 2.43, participants = 310, one study; oral nitric
oxide donor: RR 0.39, 95% CI 0.08 to 1.93, participants = 99,
one study; Analysis 1.4).
Only one class of tocolytic drugs, the beta stimulants, had a reason-
able number of trials to allow firm conclusions regarding primary
outcomes (see Summary of findings for the main comparison).
Secondary outcomes
We found a statistically significant reduction in failure of ECV
when parenteral beta stimulant drugs were used (average RR 0.70,
95% CI 0.60 to 0.82, participants = 900, nine studies, I² = 34%,
evidence graded asmoderate quality; Analysis 1.5). For other types
of tocolytics (oral beta stimulants, oral calcium channel blockers,
parenteral or sublingual nitric oxide donors), evidence was insuf-
ficient to demonstrate any differences between groups for failure
of ECV (RR 1.00, 95% CI 0.56 to 1.79, participants = 45, one
study; RR 0.93, 95% CI 0.78 to 1.11, participants = 310, one
study; RR 0.86, 95% CI 0.70 to 1.06, participants = 126, one
study; average RR 1.04, 95% CI 0.55 to 1.96, participants = 156,
two studies, respectively).
Too few studies assessed most of our other secondary outcomes
to reveal clear differences between groups. No statistically signifi-
cant differences between groups were identified for difficult ECV
(parenteral beta stimulants: RR 0.50, 95% CI 0.16 to 1.54, par-
ticipants = 63, one study; Analysis 1.6); maternal palpitation (par-
enteral beta stimulants: RR 5.00, 95% CI 0.25 to 101.89, partic-
ipants = 114, one study; parenteral nitric oxide donors: RR 0.49,
95%CI 0.05 to 5.27, participants = 117, one study; Analysis 1.7);
or maternal hypotension, which was reported for single studies ex-
amining parenteral and sublingual nitric oxide donors (RR 1.47,
95% CI 0.26 to 8.50, participants = 117, and, RR 5.88, 95% CI
0.73 to 47.07, participants = 99, respectively; Analysis 1.9).
Two studies examining the use of parenteral or sublingual nitric
oxide donors reported maternal headaches, and women receiving
active treatment were more likely to experience headache com-
paredwith those givenplacebo (RR18.68, 95%CI1.11 to 313.77,
participants = 117, and, RR 10.29, 95% CI 2.55 to 41.56, par-
ticipants = 99, respectively; Analysis 1.8).
Other outcomes were not reported or were reported in single stud-
ies, and evidence was insufficient to reveal differences between
groups receiving tocolysis versus placebo.
1. Operative vaginal birth (calcium channel blocker: RR 0.34,
95% CI 0.09 to 1.22, 310 women; Analysis 1.10).
2. Maternal mortality (not reported).
3. Maternal morbidity (not reported).
4. Perinatal mortality (calcium channel blocker: 310
participants, no events; Analysis 1.13).
5. Perinatal morbidity (not reported).
In this version of the review, we added the outcome vaginal breech
birth, which was reported in one study with no evidence of a
difference between groups (RR 1.00, 95% CI 0.30 to 3.28, one
study, 124 women; Analysis 1.15).
Non-prespecified outcomes
An additional six outcomes were reported that we had not spec-
ified in the protocol: Apgar less than seven at five minutes (beta
stimulants: no events, two studies, 227 infants), neonatal seizures
(beta stimulants: no events, one study, 124 infants), admission to
neonatal unit (beta stimulants: average RR 1.00, 95% CI 0.30
to 3.36, two studies, 238 infants; Analysis 1.18), birth trauma
(beta stimulant: no events, one study, 144 women) and flushing
in women (calcium channel blocker: RR 23.30, 95% CI 1.38 to
391.91, one study, 310 women; Analysis 1.20). We found too few
data on these outcomes to report findings with confidence.
Subgroup analysis by parity
Six studies reported the data by parity (Chung 1996;Hilton 2009;
Impey 2005; Nor Azlin 2005; Stock 1993; Tan 1989), but only
two reported data on our primary outcomes (Hilton 2009; Impey
2005). Interaction tests showednodifferences betweennulliparous
and multiparous women. Cephalic presentation in labour and at
birth was not statistically significant, but the numbers of women
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were small (average RR 1.89, 95% CI 0.98 to 3.62, two studies,
249 women, interaction test Chi² = 0.00, df = 1, P value 0.95;
Analysis 21.1). We observed a significant reduction in caesarean
sections (average RR 0.84, 95% CI 0.74 to 0.95, two studies, 249
women, interaction test Chi² = 0.68, df = 1, P = 0.41; Analysis
21.2) and in failed ECV (average RR 0.78, 95% CI 0.66 to 0.92,
six studies, 513 women, interaction test Chi² = 2.07, df = 1, P =
0.08, Analysis 21.4), with no differences between nulliparous and
multiparous women.
Subgroup analysis by study quality
We considered two studies to be at high risk of bias in terms of
randomisation, concealment of allocation or completeness of data
(Fernandez 1997; Robertson 1987); both of these studies exam-
ined parenteral beta stimulants. Even with these studies temporar-
ily excluded, parenteral beta stimulants still appeared to be effec-
tive in achieving cephalic presentation at birth (average RR 2.03,
95% CI 1.49 to 2.77, three studies, 289 women). Findings for
the outcome of failure to achieve cephalic vaginal birth remained
non-significant for parenteral beta stimulants (average RR 0.65,
95% CI 0.38 to 1.11, two studies, 238 women). There remained
a significant reduction in caesarean sections for parenteral beta
stimulants when studies at high risk of bias were temporarily re-
moved (average RR 0.75, 95% CI 0.63 to 0.89, four studies, 581
women). Fetal bradycardia remained as showing no significant dif-
ference identified.
Comparison 2. Tocolytics versus other tocolytics
(four studies with 344 women)
Four studies, or parts of studies, involving 344 women looked at
these comparisons.
Calcium channel blockers (A2) versus beta stimulants (A1):
Two studies involving 176 womenmade this comparison (Collaris
2009; Nor Azlin 2008).
Nitric oxide donors (A3) versus beta stimulants (A1):Two stud-
ies involving 168 women made this comparison (Bujold 2003b;
El-Sayed 2004).
Nitric oxide donors (A3) versus calcium channel blockers (A2):
No studies looked at this comparison.
One study involving 63 women included three groups and com-
pared two different beta stimulants - hexoprenaline and ritodrine
- versus placebo (Stock 1993). We are not comparing different
drugs within the same class, so these data are omitted from this
section (although the data are included in the section on tocolysis
versus placebo).
The overall quality of the studies was reasonable. All four studies
were assessed as being at low risk of bias in terms of both sequence
generation and allocation concealment (Bujold 2003b; Collaris
2009; El-Sayed 2004; Nor Azlin 2008). Blinding was considered
adequate in one study, in which women, staff and outcome asses-
sors were blinded (Bujold 2003b). (See Figure 1.)
Primary outcomes
We obtained too few data on these outcomes to report findings
with confidence.
Cephalic presentation at birth
1. Calcium channel blockers versus beta stimulants (RR 0.62,
95% CI 0.39 to 0.98, one study, 90 women; Analysis 2.1).
2. Nitric oxide donors versus beta stimulants (RR 0.56, 95%
CI 0.29 to 1.09, one study, 74 women; Analysis 2.1.2).
Cephalic vaginal birth not achieved
1. Nitric oxide donors versus beta stimulants (RR 1.13, 95%
CI 0.88 to 1.47, one study, 74 women; Analysis 2.2).
Caesarean section
1. Calcium channel blockers versus beta stimulants (average
RR 1.28, 95% CI 1.03 to 1.59, two studies, 170 women;
Analysis 2.3).
Fetal bradycardia
1. Calcium channel blockers versus beta stimulants (average
RR 1.17, 95% CI 0.46 to 3.03, two studies, 170 infants;
Analysis 2.4).
2. Nitric oxide donors versus beta stimulants (RR 1.06, 95%
CI 0.16 to 7.10, one study, 74 infants; Analysis 2.4.1).
Secondary outcomes
Failed ECV
1. Calcium channel blockers versus beta stimulants (average
RR 1.41, 95% CI 1.06 to 1.86, two studies, 176 women;
Analysis 2.5.1).
2. Nitric oxide donors versus beta stimulants (average RR
1.48, 95% CI 1.13 to 1.94, two studies, 133 women; Analysis
2.5.2).
Difficult ECV
1. Calcium channel blockers versus beta stimulants (RR 5.22,
95% CI 0.26 to 105.81, one study, 90 women; Analysis 2.6).
Non-prespecified outcomes
Other non-prespecified outcomes (maternal palpitations,
headache, hypotension and infant admission to neonatal intensive
care unit) were reported in single studies with small sample sizes,
and evidence was insufficient to allow firm conclusions.
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Subgroup analysis by parity
One small study involving 86 women compared nifedipine versus
terbutaline and reported data by parity (Nor Azlin 2008). Failed
ECV, the only outcome reported by parity, did not show a sig-
nificant difference between the two tocolytic drugs, although the
interaction tests showed no differences between nulliparous and
multiparouswomen (RR1.38, 95%CI 0.90 to 2.13, one study, 86
women interaction test Chi² = 0.35, df = 1, P value 0.55; Analysis
22.4).
Sensitivity analyses by study quality
Studies were insufficient for this analysis.
Comparison 3. Vibroacoustic stimulation in midline
fetal spine positions versus placebo (one study, 26
women)
One study involving 26 women (of whom 23 provided data)
looked at this comparison and reported only on the number of
women in whom ECV failed (Johnson 1995). The quality of the
study was reasonable, but only 26 women were included. So the
finding of a statistically significant reduction in failed ECV cannot
be relied upon (RR 0.09, 95% CI 0.01 to 0.60, one study, 23
women; Analysis 3.5).
Other primary and secondary outcomes were not reported.
Comparison 4. Vibroacoustic stimulation versus
tocolytics
We found no studies assessing this comparison.
Comparison 5. Comparison of different types of
vibroacoustic stimulation
We found no studies assessing this comparison.
Comparison 6. Regional analgesia versus placebo (six
studies, 554 women)
Six studies involving 554 women looked at this comparison. Four
of these studies addressed the effect of spinal analgesia on ECV
(Delisle 2001; Dugoff 1999;Weiniger 2007;Weiniger 2010); two
studies assessed the effect of epidural analgesia (Mancuso 2000;
Schorr 1997).
All studies except one (Delisle 2001) used a tocolytic drug as well
in both arms; the one exception allowed clinicians to choose to use
a tocolytic drug if they wished (Delisle 2001). This study reported
on very few of our prespecified outcomes. We have analysed sepa-
rately the use of regional analgesia with or without tocolysis. Find-
ings for primary outcomes for regional analgesia (with tocolysis)
are set out in Summary of findings 2.
The quality of the studies was generally unclear. Only two studies
were considered to have low risk of bias in terms of sequence
generation and allocation concealment (Mancuso 2000; Schorr
1997). The remainder of the studies were mostly unclear around
risk of bias (Figure 1).
Primary outcomes
For regional analgesia with tocolysis versus tocolysis alone, we
found no statistically significant differences identified for the pri-
mary outcomes: cephalic presentation at labour and at birth (aver-
age RR 1.44, 95%CI 0.78 to 2.66, three studies, 279 women, ran-
dom-effects, Tau² = 0.24, I² = 80%, Chi² P value 0.006; Analysis
6.1); caesarean section (average RR 0.74, 95% CI 0.40 to 1.37,
three studies, 279 women, random-effects, Tau² = 0.26, I² = 88%,
Chi² P value 0.0003; Analysis 6.3); and fetal bradycardia (average
RR 1.48, 95%CI 0.62 to 3.57, two studies, 210 women, random-
effects, Tau² = 0.05, I² = 8%, Chi² P value 0.30; Analysis 6.4).
Failure to achieve cephalic vaginal delivery was not reported.
Secondary outcomes
We did identify a significant reduction in the number of failures
of ECV with regional analgesia with tocolysis (RR 0.61, 95% CI
0.43 to 0.86, participants = 409, five studies, I² = 56%; Analysis
6.5). This outcome was also reported in the single study exam-
ining regional analgesia without tocolysis versus no intervention,
and no evidence suggested a difference between groups (RR 0.89,
95% CI 0.70 to 1.14, participants = 141). None of our other sec-
ondary outcomes were reported (operative vaginal birth, maternal
mortality, maternal morbidity, perinatal mortality, perinatal mor-
bidity).
Outcomes not prespecified
Some studies assessed placental abruption and maternal discom-
fort but identified no differences with regional analgesia. Three
studies examined maternal hypotension, and regional analgesia
with tocolysis was associated with increased risk of hypotension
(average RR 11.58, 95% CI 1.53 to 87.50, participants = 280,
three studies, I² = 0%; Analysis 6.9).
Subgroup analysis by parity
Six studies reported data by parity, but it was not possible to un-
dertake any subgroup analysis.
Sensitivity analysis by study quality
Good quality data were insufficient for subgroup sensitivity analy-
sis for this comparison, as only two (Mancuso 2000; Schorr 1997)
of the six identified were considered to have low risk of bias in
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terms of randomisation, concealment of allocation or complete-
ness of data.
Comparison 7. Regional analgesia versus tocolytics
We found no studies assessing this comparison.
Comparison 8. Regional analgesia versus
vibroacoustic stimulation
We found no studies assessing this comparison.
Comparison 9. Comparison of different types of
regional analgesia
We found no studies assessing this comparison.
Comparison 10. Amnioinfusion versus placebo
We found no studies assessing this comparison.
Comparison 11. Amnioinfusion versus tocolytics
We found no studies assessing this comparison.
Comparison 12. Amnioinfusion versus vibroacoustic
stimulation
We found no studies assessing this comparison.
Comparison 13. Amnioinfusion versus regional
analgesia
We found no studies assessing this comparison.
Comparison 14. Comparison of different types of
amnioinfusion
We found no studies assessing this comparison.
Comparison 15. Systemic opioids versus placebo (one
study, 60 women)
One study with 60 women was included in this compari-
son (Munoz 2014); in this trial intravenous patient-controlled
remifentanil was compared with an intravenous placebo.
Primary outcomes
Presentation at birth was not reported. Trialists reported “tran-
sient” fetal bradycardia, but the study was underpowered to
demonstrate a statistically significant difference between groups
(RR 0.31, 95% CI 0.09 to 1.04; Analysis 15.3). The frequency
of caesarean section was very similar in the two groups (RR 0.99,
95% CI 0.63 to 1.57) (Analysis 15.4).
Secondary outcomes
No clear evidence was found of a difference between groups in
failure of ECV (RR 0.77, 95% CI 0.47 to 1.26; Analysis 15.5) nor
in frequency of operative vaginal birth (RR 0.94, 95% CI 0.20 to
4.27; Analysis 15.10).
Other secondary outcomes were not reported.
Other outcomes
Several non-prespecified outcomes were reported in this trial.
Women receiving the opioid had lower pain scores compared with
control participants (mean difference (MD) -1.80 (on a 10-point
scale), 95% CI -3.04 to -0.56; Analysis 15.15), and maternal sat-
isfaction with the procedure was increased in the group receiving
remifentanil (MD2.60, 95%CI 1.25 to 3.95; Analysis 15.16).No
significant difference between groups was found in maternal side
effects (nausea and vomiting, dizziness and drowsiness), although
the study was underpowered to demonstrate differences for most
outcomes (Analysis 15.17; Analysis 15.18; Analysis 15.19).
Comparison 16. Systemic opioids versus tocolytics
We found no studies assessing this comparison.
Comparison 17. Systemic opioids versus
vibroacoustic stimulation
We found no studies assessing this comparison.
Comparison 18. Systemic opioids versus regional
analgesia
One study, involving 95 women, assessed this comparison (
Sullivan 2009). The quality of the study was good; only lack of
blindingmight contribute to bias. The remaining assessmentswere
consistent with low risk of bias (Figure 1).
Primary outcomes
The rate of cephalic presentation at birth was not reported. No
significant differences between groups were reported for the out-
come failure to achieve vaginal cephalic birth (RR 1.18, 95% CI
0.90 to 1.54). Also no clear difference between groups was seen
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in terms of the numbers of women undergoing caesarean section
(RR 1.18, 95% CI 0.90 to 1.54, 95 women; Analysis 18.3). A
similar rate of fetal bradycardia was observed in the two groups
(RR 0.71, 95% CI 0.24 to 2.09, 94 women; Analysis 18.4).
Secondary outcomes
No statistically significant difference was observed in frequency of
failure of ECVwhen a systemic opioidwas comparedwith regional
analgesia (RR 1.29, 95% CI 0.93 to 1.80, 95 women; Analysis
18.5).
Comparison 19. Systemic opioids versus
amnioinfusion
We found no studies assessing this comparison.
Comparison 20. Comparison of different systemic
opioids
We found no studies assessing this comparison.
Comparison 23. Hypnosis versus neurolinguistic
programming (one study, 80 women)
One study with 80 women compared two types of hypnosis.
Primary outcomes
No primary outcomes were reported.
Secondary outcomes
No significant evidence suggested that one hypnosis technique
was more effective than the other (RR 1.08, 95% CI 0.74 to
1.57; Analysis 23.5), and women in both groups reported a similar
degree of pain relief during the procedure, as measured on a scale
of one to 10 (MD 0.10, 95% CI -0.87 to 0.67, one study, 80
women (non-prespecified outcome); Analysis 23.15).
Comparison 24. Talcum powder versus gel to assist
with ECV (one study, 95 women)
One study compared the use of talcum powder versus gel applied
to the woman’s abdomen to assist with ECV. If after one round of
attempts (two attempts) using the allocated method, ECVwas not
successful, the alternative method could be tried. This meant that
many of the women in the trial with initial failed ECV crossed over
to the other method; outcome data were very difficult to interpret
because although analysis was performed according to original
allocation, womenmay have received both methods. We therefore
report here only the secondary outcome related to failure of ECV
after the first round of attempts (using the allocated method).
There was insufficient evidence to demonstrate whether talcum
was more or less effective than gel in assisting version (RR 1.26,
95% CI 0.84 to 1.89, one study, 80 women; Analysis 24.5).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Regional analgesia (with tocolysis) versus no intervention of regional analgesia (with or without tocolysis) for breech presentation
Patient or population: pat ients with breech presentat ion
Settings: studies in hospital sett ings
Intervention: regional analgesia (with tocolysis) versus no intervent ion of regional analgesia (with or without tocolysis)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Regional analge-
sia (with tocolysis) vs
no intervention of re-
gional analgesia (with
or without tocolysis)
Cephalic presentation
at birth (primary)
Study population RR 1.63
(0.75 to 3.53)
279
(3 studies)
⊕©©©
Very low1,2,3
393 per 1000 640 per 1000
(295 to 1000)
Moderate
352 per 1000 574 per 1000
(264 to 1000)
Cephalic vaginal birth
not achieved (CS +
breech vaginal birth)
(primary)
Study population RR 0.65
(0.47 to 0.89)
108
(1 study)
⊕⊕©©
Low4,5
741 per 1000 481 per 1000
(348 to 659)
Moderate
741 per 1000 482 per 1000
(348 to 659)21
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Caesarean section
(primary)
Study population RR 0.74
(0.4 to 1.37)
279
(3 studies)
⊕©©©
Very low1,2,3
650 per 1000 481 per 1000
(260 to 891)
Moderate
685 per 1000 507 per 1000
(274 to 938)
Fetal bradycardia (pri-
mary)
Study population RR 1.48
(0.62 to 3.57)
210
(2 studies)
⊕⊕©©
Low1,3
85 per 1000 126 per 1000
(53 to 303)
Moderate
86 per 1000 127 per 1000
(53 to 307)
Failed external
cephalic version
Study population RR 0.61
(0.43 to 0.86)
409
(5 studies)
⊕⊕⊕©
Moderate1
585 per 1000 357 per 1000
(251 to 503)
Moderate
577 per 1000 352 per 1000
(248 to 496)
Perinatal morbidity See comment See comment Not est imable 0
(0)
See comment No data reported
Perinatal mortality See comment See comment Not est imable 0
(0)
See comment No data reported
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* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. All studies contribut ing data had design lim itat ions.
2. I2 > 60%; direct ion and size of ef fect inconsistent.
3. Wide 95% CI crossing the line of no ef fect and small sample size.
4. Study contribut ing data had design lim itat ions.
5. Est imate based on small sample size.
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D I S C U S S I O N
Summary of main results
Parenteral beta stimulants, used to help external cephalic version
of breech babies, were effective in increasing the number of women
going into labour with their baby in a cephalic presentation and
in reducing the number of women undergoing caesarean section.
However, data on possible adverse effects are insufficient. Data
derived by comparison of other classes of tocolytic drugs (calcium
channel blockers and nitric acid donors) were also insufficient. We
identified no difference in response between nulliparous women
and multiparous women in terms of successful external cephalic
version (ECV), babies in the cephalic presentation during labour
and caesarean section.
Use of regional analgesia, in combination with a tocolytic drug,
to facilitate ECV was effective in terms of increasing successful
versions, but the data show no benefit in terms of babies in the
cephalic presentation during labour or reduction in caesarean sec-
tions.
Data were insufficient on the use of vibroacoustic stimulation, am-
nioinfusion, systemic opioids, hypnosis or abdominal lubricants
for helping to turn breech babies using ECV techniques.
Overall completeness and applicability of
evidence
Available evidence does not describe many of the prespecified out-
comes, in particular, possible adverse effects.
Quality of the evidence
The overall quality of the evidence was reasonable, with studies
on regional analgesia unable to be blinded. However, several as-
sessments will have yielded insufficient data to provide an answer
with any degree of assurance. We carried out formal assessments
of quality of the evidence using GRADEpro for parenteral beta
stimulants and regional analgesia with tocolysis. For both of these
comparisons, the evidence was graded from moderate to very low
quality.
Potential biases in the review process
Evidence in this review was derived from studies identified in a
detailed search process. Trials comparing interventions to help
external cephalic version of breech babies at term that have not
been published may not have been identified. We attempted to
minimise bias in the review process by having two review authors
independently extract data.
Agreements and disagreements with other
studies or reviews
We are not aware of any other systematic reviews on this topic.
Studies within the review seem to be in reasonable agreement.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Beta stimulant tocolytics, given parenterally to facilitate external
cephalic version of breech babies, increased the number of babies
in the cephalic presentation during labour and birth, and reduced
the number of caesarean sections performed. However, insuffi-
cient data were collected on possible adverse effects on mother or
baby. Other groups of tocolytics, calcium channel blockers and
nitric acid donors yielded insufficient data to provide good evi-
dence. Data on other possible facilitators of external cephalic ver-
sion (ECV) were insufficient to provide useful evidence.
Use of regional analgesia in combination with tocolytic drugs in-
creased the rate of success of ECV, but data were insufficient to
indicate whether this was associated with an increase in cephalic
presentation at birth or a change in the rate of caesarean section.
Implications for research
Future research needs to carefully assess any potential adverse ef-
fects on both mother and baby.
Routine tocolysis for ECV at term
Further controlled trials of routine tocolysis for ECV at term are
needed. In particular, possible benefits of routine tocolysis used
to reduce the force required for successful ECV, and possible risks
of maternal cardiovascular side effects, need to be addressed fur-
ther. Additional trials are also needed to compare the effectiveness
of routine versus selective use of tocolysis; investigators should
include short-term and long-term outcome measures that assess
morbidity according to type of birth.
Although randomised trials of nitroglycerine have been small, the
results are sufficiently negative to discourage further trials.
Fetal acoustic stimulation for ECV at term
The results presented in this review are sufficiently encouraging to
justify further trials of this procedure. Short-term and long-term
outcomes must be assessed.
Regional analgesia for ECV at term
Further trials are needed. The effect of vaginal displacement of the
presenting part should be assessed. Fluid received by the regional
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analgesia group and by the control group should be similar, and
whether tocolytic agents should be used adjunctively needs further
investigation.
Amnioinfusion for ECV at term
Transabdominal amnioinfusion to increase amniotic fluid volume
might facilitate ECV and should be investigated.
Hydration to increase amniotic fluid volume for ECV
at term
Intravenous or oral hydration before ECV attempts to increase
amniotic fluid volume should be investigated as a separate inter-
vention (Hofmeyr 2002).
Systemic opioids for ECV at term
Given the general adverse effects of opioids (Bricker 2002), re-
search might be better focused on other possible facilitators for
ECV of breech babies.
Other interventions
Evidence on other interventions such as hypnosis or abdominal
lubricants is insufficient; adequately designed and powered trials
may throw light on whether such interventions are worthwhile.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bujold 2003a
Methods RCT.
Participants Inclusion criteria: women with singleton breech pregnancy at 36 to 40 weeks’ gestation
Women also givenNST andUS evaluation for EFW, fetal morphologic features, AFI and
placental location. After NST, if women met criteria, clinician verified breech mobility
by abdominal palpation. N = 99
Exclusion criteria: IUGR (defined as an EFW (determined by US examination, < 10th
percentile for GA), oligohydramnios (defined as AFI≤ 5 cm), presence of a placenta pre-
via or an abruptio placenta, a previous uterine scar other than a low transverse caesarean
delivery, active labour, rupture of membranes, fetal anomalies incompatible with life, a
non-mobile breech by abdominal palpation, any contraindication to vaginal delivery, a
medical/allergic contraindication to nitroglycerine
Interventions Intervention: tocolysis: nitroglycerine - nitric oxide donor (A3) - sublingual.
2 sublingual sprays of 400 micrograms nitroglycerine given 3 minutes before ECV. N =
50
Comparison: placebo: 2 sublingual sprays of placebo given 3 minutes before ECV. N =
49
Outcomes ECV success (at end of procedure); vertex presentation at labour and at birth; vaginal
birth; CS; headache; blood pressure; maternal tachycardia; birthweight
Notes Sainte-Justine Hospital, April 1999 to August 2002.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised randomisation table.
Allocation concealment (selection bias) Low risk Placebo-controlled trial with identical preparations.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, clinician and assessor were blinded. Intravenous
ritodrine and placebowere supplied in identical form; sublingual
nitroglycerine and placebo were also supplied in identical form
by the hospital pharmacy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, clinician and assessor were blinded. Intravenous
ritodrine and placebowere supplied in identical form; sublingual
nitroglycerine and placebo were also supplied in identical form
by the hospital pharmacy
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Bujold 2003a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No indication of loss of participants.
Not mentioned whether the analysis was intention-to-treat; ap-
pears that a total of 99 women were randomly assigned and all
completed
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol, but the trial authors said
they would compare the rate of vertex presentation at time of
birth and the rate of vertex vaginal birth. They reported only
that there was no difference and have not provided data. Other
outcomes may also be left out
Other bias High risk Halfway through the trial, an interim analysis was performed by
the data safetymonitoring board. This board decided to stop the
trial because of a statistically significant (P value < 0.01) higher
rate of side effects and a trend toward a lower rate of successful
ECV in 1 group. This decision was based on the likelihood (<
1%) that that group would ultimately show a significant increase
in the success rate of ECV, and the likelihood (> 95%) that the
subsequently randomly assigned women would be exposed to
increased risk of adverse outcomes without potential benefit if
the trial was completed. Investigators were informed, and the
trial was stopped
No statistically significant differences were observed between the
2 groups with regard to maternal age, GA, EFW, AFI, placental
location and type of breech
Bujold 2003b
Methods RCT.
Participants Inclusion: women with singleton breech pregnancy at 36 to 40 weeks’ gestation. N =
74
Exclusion criteria: IUGR, oligohydramnios, placenta praevia, placenta abruptio, uterine
scar other than low transverse CS, active labour, ruptured membranes, fetal anomalies
incompatible with life, any contraindication to vaginal birth, contraindications to trial
medications, non-reactive CTG. CTG and US performed
Interventions Intervention: tocolysis - nitroglycerine - nitric oxide donor (A3) - sublingual.
Nitroglycerine, 2 sublingual sprays of 400 micrograms nitroglycerine plus IV placebo.
N = 38
Comparison: tocolysis - ritodrine - beta stimulant (A1) - parenteral.
Ritodrine 15 mg in 1.5 mL plus 20 mL 5% dextrose water by IVI at 111 micrograms
per minute, plus placebo sublingual spray. N = 36
Maximum 4 ECV attempts with US control.
Outcomes Rate of successful ECV; headaches; blood pressure; maternal heart rate; palpitations,
hypotension and prolonged fetal heart rate decelerations (fetal bradycardia)
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Bujold 2003b (Continued)
Notes Sainte-Justine Hospital, April 1999 to August 2001.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised table of randomisation. For every 6 women who
were entered, 3 women were assigned to the ritodrine group and
3 women were assigned to the nitroglycerine group
Allocation concealment (selection bias) Low risk Placebo-controlled trial with identical preparations.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk IV ritodrine and placebowere supplied by the hospital pharmacy
in identical form; sublingual nitroglycerine and placebo were
also supplied by the hospital pharmacy in identical form. The
nurse and the attending physician were blinded to the contents
of the infusion or the sublingual spray
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk IV ritodrine and placebowere supplied by the hospital pharmacy
in identical form; sublingual nitroglycerine and placebo were
also supplied by the hospital pharmacy in identical form. Staff
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No indication suggested that any women were excluded after
randomisation or were lost to follow-up
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk Study stopped after 74 women were enrolled because ritodrine
was withdrawn from the market in July 2001 - not because of
benefit
No statistically significant differences between the 2 groups with
regard to maternal age, GA, maternal weight, AFI and Frank
breech. However, a significant difference was observed between
the 2 groups at admission with respect to mean blood pressure
(mm Hg)* at admission for the ritodrine group: 98 (67-125);
mean blood pressure (mm Hg)* at admission for the nitroglyc-
erine group: 90 (75-106) (P value 0.03)
Chung 1996
Methods RCT, stratified by parity.
Participants Inclusion criteria: women with singleton breech presentation, as confirmed by US, at
36 to 38 weeks’ gestation. N = 51 recruited but 50 analysed
Exclusion criteria: contraindication to tocolytic therapy, scarred uterus, antepartum
haemorrhage, hypertension, impaired fetal growth, oligohydramnios, vaginal delivery
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Chung 1996 (Continued)
contraindicated, abnormal umbilical artery Doppler flow pattern
Interventions Intervention: tocolytic: ritodrine - beta stimulant (A1) - parenteral
IVI of ritodrine 0.4 mg/mL in 5% dextrose at 1.5 mL/min via an infusion pump, for
15 minutes before and during ECV attempt. If uterine contractions appeared to be
preventing successful version, the infusion rate was increased in steps of 0.75 mL/min.
Compared with matching 5% dextrose infusion. ECV attempted by 2 investigators,
followed by repeat US scan and CTG. N = 25
Comparison: placebo: N = 25.
Outcomes Failed ECV attempt.Other data presented according to successful or failed ECV attempt:
non-cephalic presentation at birth (1/24 vs 23/26); CS (5/24 vs 19/26). 1 intrauterine
death occurred 4 weeks after successful ECV (group not stated)
Subgroup analysis showed that statistically significant benefit was limited to nulliparous
women
Notes Paired sequential analysis reached significance after 10 pairs. Trial was continued because
of erroneous statistical calculations. Thereafter little benefit was seen from tocolysis.
Study authors suggest that tocolysis is helpful only during the learning phase of the
technique. A subsequent trial (published earlier) from the same group showed no benefit
of tocolysis (Stock 1993).
Nulliparous and parous women randomly assigned separately.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers: sequential paired
design.
Allocation concealment (selection bias) High risk Randomisation code was known to 1 of the authors who
attended each woman throughout the procedure and for 20
minutes thereafter. He did not take part in version attempts.
It is not clear whether allocation in pairs may have enabled
the unblinded study author to know the next allocation in
some cases, which could introduce selectionbias, as could the
study author knowing the code even if he did not undertake
the procedure
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participant was blinded; 2 doctors who attempted the ver-
sion were blind to randomisation throughout, but the code
was known to a third review author, who was in attendance
throughout
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Participant was blinded; 2 doctors who attempted the ver-
sion were blind to randomisation throughout, but the code
was known to a third review author, who was in attendance
throughout
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Chung 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman was excluded because of absent end-diastolic flow
in the umbilical artery before commencement of the proce-
dure (unclear whether they were excluded before randomi-
sation)
Unclear whether the analysis was intention-to-treat.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk Groups judged by study authors to be similar in age, parity
and mean gestation (Table 1, page 721)
Collaris 2009
Methods RCT.
Participants Inclusion criteria:womannot in labour, with singletonpregnancy in breech or transverse
lie at 36 to 41 weeks’ gestation. N = 90
Exclusion criteria: in keeping with recommendations of the American College of Ob-
stetricians and Gynecologists on ECV
Interventions Intervention: tocolytic: nifedipine - calcium channel blocker (A2) - oral.
Oral nifedipine (10 mg) and SQ saline placebo. N = 44.
Comparison: tocolytic: terbutaline - beta stimulant (A1) - parenteral.
Subcutaenous terbutaline (250 micrograms) with oral placebo. N = 46
Outcomes Primary outcomes were successful ECV and CS.
Secondary outcomes were cephalic fetal presentation at delivery, numerical rating score
for satisfaction with ECV, preference for injection or tablet, post ECV. Also, CTG
assessment, labour onset, prelabour membrane rupture and various neonatal outcomes
Notes Women who had a failed ECV on first attempt could be re-randomised. Study authors
did a primary analysis on 90 women, but then undertook a secondary analysis by adding
in repeat ECV attempts. We will consider only the primary analysis data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, variable blocks of 8 or 12.
Allocation concealment (selection bias) Low risk No indication that this was an issue; did use sequential opening
of sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and providers blinded; unclear whether outcome
assessor was blinded
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Collaris 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Participants and providers blinded; unclear whether outcome
assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk For some outcomes, data were collected only for a subset of
participants; CTGs of 7 women (7%) were missing from the
files
Analysis of participants at primary enrolment was performed
on an intention-to-treat basis. All women received treatment as
allocated
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk No significant differences were noted in baseline criteria; no
other biases were apparent
Delisle 2001
Methods RCT.
Participants Inclusion criteria: singleton non-vertex; age 18 or older; GA 36 weeks or more; intact
membranes; reactive CTG. N = 141
Interventions Intervention: regional analgesia (C).
Spinal analgesia with bupivacaine 0.25% 1 mL plus 20 mcg fentanyl vs control; 4 ECV
attempts. N = 73
Comparison: standard care. N = 68.
Nitroglycerine tocolysis was used per operator preference.
Outcomes ECV failure; non-reassuring CTG (1/73 vs 0/68).
Notes Conference abstract, August 1998 to June 2001.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information given.
Allocation concealment (selection bias) Unclear risk No information given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and clinicians were not blinded; unclear whether
outcome assessor was blinded
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Delisle 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Participants and clinicians were not blinded; unclear whether
outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Little information given.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias High risk Baseline data: reported as similar in maternal age, GA at time
of ECV, parity and birthweight. However, clinicians, who were
not blinded to the intervention, were able to give IV tocolysis
by choice; this could lead to an imbalance between groups. No
information on this is given in the Conference abstract, but this
is a potential source of bias
Dugoff 1999
Methods RCT.
Participants Inclusion criteria: breech presentation, 36 weeks or more, reactive CTG, intact mem-
branes, minimum 2 × 2 cm pocket of amniotic fluid. N = 102 in the main paper (in
abstract, reported as 101 women)
Exclusion criteria: gross fetal anomaly, uterine malformation, EFW > 4000 g, fetal
growth restriction, placenta praevia, third-trimester vaginal bleeding, labour, contraindi-
cations to spinal analgesia or terbutaline
Interventions Intervention: regional analgesia (C) + tocolytic.
Spinal analgesia with 10 mcg sufentanil and 1 mL 0.25% bupivacaine and 500 mL
lactated Ringer’s prehydration. N = 50 (49 in abstract; we will use detail from the detailed
publication)
Comparison: standard care + tocolytic. N = 52.
ECVwith terbutaline 0.25mg was attempted usually by 2 operators, and was stopped for
fetal bradycardia, maternal discomfort. Up to 4 attempts were allowed. Vaginal elevation
of the presenting part not used
Outcomes Successful ECV; breech delivery; CS.
Notes University of Colorado Health Sciences Centre and Denver Health Medical Centre,
USA. October 1993 to August 1997
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, computer-generated sequence.
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Dugoff 1999 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation by cards in sealed envelopes. Cards designating
“spinal” or “no spinal” were placed in sealed opaque envelopes
that were opened after women signed informed consent forms
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Likely that the women and the clinician were not blinded to
whether or not women received an epidural
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of whether investigators were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Spontaneous version occurred before ECV in 4 women in the
spinal group (after the spinal was given) and in 1 woman in the
no spinal group. These women were included in the intention-
to-treat analysis
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk No differences in baseline characteristics were noted.
El-Sayed 2004
Methods RCT - with cross-over for some unsuccessful ECVs.
Participants Inclusion criteria: term singleton pregnancy with breech presentation. N = 59.
Exclusion criteria: Maternal exclusion criteria included chronic hypertension,
preeclampsia, placental abruption, placenta praevia, maternal cardiac disease, chorioam-
nionitis and previous uterine surgery
Fetal exclusion criteria included ruptured membranes, IUGR (EFW < 10th centile for
GA by US), decreased AFI or oligohydramnios, fetal anomalies incompatible with life
and an extended fetal head
Interventions Intervention: tocolytic: nitroglycerine - nitric oxide donor (A3) - parenteral.
IV nitroglycerin (100 µg IV × 2). N = 30.
Comparison: tocolytic: terbutaline - beta stimulant (A1) - parenteral.
Terbutaline (0.25 mg SQ). N = 29.
After successful ECV, the decision to induce then or wait for spontaneous labour was
left to the doctor. After failed ECV, the options were intervention with the other drug
in the trial, discharge with appointment for CS or immediate CS; the decision was left
to the doctor
Outcomes Successful ECV; difficult ECV; palpitations; headaches; method of delivery; light-head-
edness; flushing; reversion (back to breech after ECV)
Notes We have used only data on initial “Failed ECV” because of the cross-over element of this
study. We are contacting study authors to clarify the other outcome data
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El-Sayed 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation done by a third party not
involved in the trial. 30 labels bearing the
word ’nitroglycerin’ and 30 labels bearing
the word ’terbutaline.’ Labels were placed
on 60 unmarked opaque envelopes, which
were sealed, shuffled thoroughly and num-
bered sequentially
Allocation concealment (selection bias) Low risk Labelswere placed on60unmarked opaque
envelopes, which were sealed and num-
bered sequentially
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participant or doctor. Dif-
fering routes of administration of drugs,
IV or SQ, meant that people would know
which drug was being administered
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether the assessor was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1woman was assigned to terbutaline before
it was confirmed that the baby was breech;
excluded as fetus had a cephalic presenta-
tion. This was considered insufficient to in-
fluence the analysis
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk No statistically significant differences in
pretreatment maternal or fetal characteris-
tics (see Table 1, on p 2053). These were
maternal age, GA at ECV, multiparity,
EFW, body mass index, anterior placenta
and ECV by maternal-fetal medicine at-
tending
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Fernandez 1997
Methods RCT.
Participants Inclusion criteria: singleton, non-cephalic pregnancy; > 36 weeks’ gestation. N = 103
Exclusion criteria: younger than 17 years of age, prior uterine surgery, ruptured mem-
branes, placenta praevia, anomalous fetus, multiple gestation, sensitivity to terbutaline,
other maternal medical complications
Interventions Intervention: tocolytic: terbutaline - beta stimulant (A1) - parenteral.
Terbutaline 0.25 mg in unlabelled insulin syringe given SQ 15 to 30 minutes before
ECV attempts. Forward then backward roll attempted. N = 52
Comparison: placebo. N = 51.
Outcomes Successful ECV; CS.
Notes Parkland Memorial Hospital, Dallas, Texas, USA. January 1994 to June 1995
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised computer tables - randomisation by pharmacy us-
ing computer-generated random sequence
Allocation concealment (selection bias) Unclear risk No mention in article.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Terbutaline or placebo obtained from pharmacy in unlabelled
syringe. Placebo was an equal volume of normal saline
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo-controlled trial with blinding of staff.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusion of women or loss to follow-up. Appears to be an
intention-to-treat analysis
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk With exception of maternal age, the 2 groups did not differ at
baseline. Mean age for terbutaline group: 23.4. Mean age for
placebo group: 25.7
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Hilton 2009
Methods RCT, stratified by parity and hospital.
Participants Inclusion criteria: non-cephalic singleton pregnancies over 37 weeks with normal AFI.
Participants split into nulliparous (N = 82) and multiparous (N = 44). N = 126
Exclusion criteria: labour, ruptured membranes, history of third-trimester bleeding,
any preexisting uterine scar, pregnancy-induced hypertension or gestational diabetes,
oligohydramnios, hydramnios, IUGR, macrosomia, maternal hypotension, inability to
comprehend the consent form
Interventions Intervention: tocolytic: nitroglycerine - nitric oxide donor (A3) parenteral.
IV nitroglycerine (10mLof 100micrograms/mL).N =65 (nulliparous = 42,multiparous
= 23)
Comparison: placebo. N = 61 (nulliparous = 40, multiparous = 21).
Outcomes ECV success; cephalic presentation at delivery; CS rate; maternal discomfort; headaches;
flushing; hypotension; palpitations; fetal heart rate abnormalities
Notes Nulliparous group: 4 women excluded after randomisation. In experimental group, 1
excluded for pregnancy-induced hypertension, and 1 excluded for decreased AFI. Con-
trol group: 1 excluded as woman was in labour, and 1 excluded because of cephalic
presentation. 1 woman in placebo group lost to follow-up
Multiparous group: 3 women excluded after randomisation. In experimental group, 2
excluded as presentation was cephalic at the time of version. In placebo group, 1 woman
excluded as presentation was cephalic at time of version
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation tables used.
Allocation concealment (selection bias) Low risk Using separate randomisation sequences for
nulliparous and multiparous women at each
hospital site, participants were assigned a study
number from sequentially numbered opaque
envelopes. The study number was forwarded to
the pharmacy, and allocated treatmentwas pro-
vided on the basis of the corresponding study
number from randomisation tables kept in the
pharmacy. No further details provided on ran-
domisation sequences used
Group of allocation was unknown to obstetri-
cian, nurse, anaesthesiologist and woman
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatment was prepared as 10 mL of clear fluid
in a 10 mL syringe with 10 mL of 100 mi-
crograms/mL of nitroglycerin for women in
the nitroglycerin group, or 10 mL of normal
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Hilton 2009 (Continued)
saline for women in the placebo group. Sy-
ringes for nitroglycerine and placebo were vi-
sually indistinguishable. Group for allocation
was unknown to obstetrician, nurse, anaesthe-
siologist and woman
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Treatment was prepared as 10 mL of clear fluid
in a 10 mL syringe with 10 mL of 100 mi-
crograms/mL of nitroglycerin for women in
the nitroglycerin group, or 10 mL of normal
saline for women in the placebo group. Sy-
ringes for nitroglycerine and placebo were vi-
sually indistinguishable. Group for allocation
was unknown to obstetrician, nurse, anaesthe-
siologist and woman
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman lost to follow-up.
No apparent exclusion of women after ran-
domisation.
7 women did not undergo ECV, but their out-
comes were included in the analysis
Nulliparous group: 2 in nitroglycerine group
excluded: 1 had pregnancy-induced hyperten-
sion, 1 had a decreased AFI
Nulliparous group: 2 in placebo group ex-
cluded: 1 cephalic, 1 lost to follow-up
Multiparous group: 2 in nitroglycerine group
excluded: had cephalic presentations
Multiparous group: 1 in placebo group ex-
cluded: had cephalic presentation
Data on fetal heart rate abnormalities were
available for 61 women in nitroglycerine group
and 58 in placebo group; for side effects, the
numbers were 59 and 58, respectively
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk Baseline data: similar for maternal age, GA
and anterior placenta in nulliparous and mul-
tiparous trials
Impey 2005
Methods RCT.
Participants Inclusion criteria: nulliparous women, singleton breech presentation at 36 weeks, or
multiparous at 37 or more weeks. Eligible for inclusion if an unsuccessful attempt at
ECV (without tocolysis) was reported, with normal CTG. N = 144
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Impey 2005 (Continued)
Exclusion criteria: preexisting indication for CS, unstable lie, fetal compromise (ab-
dominal circumference below 3rd centile, either umbilical artery resistance index above
97th centile or deepest amniotic fluid pocket 2 cm, rhesus isoimmunisation
Interventions Intervention: tocolytic: ritodrine - beta stimulant (A1) - parenteral.
Tocolysis administered as ritodrine hydrochloride (Yutopar infusion of 50 mg (10 mg/
mL)) added to 12 mL dextrose saline (total 17 mL of ritodrine 3 mg/mL). N = 62
Comparison: placebo: 17 mL dextrose saline infusion by the same route at the same
rate. N = 62
Outcomes Primary outcome cephalic presentation at birth.
Secondary outcomes: incidence of successful ECV, CS, length of hospital inpatient stay,
incidence of neonatal Apgar scores < 7 at 5 minutes, neonatal admission, rare neonatal
outcomes and mean cord arterial pH. McGill pain scale was used to measure intensity
of pain
Notes Setting: BreechClinic, JohnRadcliffeHospital, Oxford: women from community clinics
and other local hospitals were referred in at 36 or 37 weeks’ gestation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated in a ratio of 1:1 using random block sizes
up to 20
Allocation concealment (selection bias) Low risk Sealed opaque envelopes opened in sequential order.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Specific detail missing, but states same infusion, same timeline,
same observation for both control and intervention
In discussion, study authors identified problems with blinding
of researcher and medical practitioner as potential threats
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Specific detail missing, but states same infusion, same timeline,
same observation for both control and intervention
In discussion, study authors identified problems with blinding
of researcher and medical practitioner as potential threats
Incomplete outcome data (attrition bias)
All outcomes
Low risk Potential sample 505, of whom 284 were deemed eligible for
inclusion in the trial. Of these, 13 refused and 47 were not
offered
All 124 participants (62 in each arm) completed the trial.
Intention-to-treat analysis.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk No differences in age or gestation seen in baseline data.
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Johnson 1995
Methods RCT cross-over - using here only data from first part.
Participants Inclusion criteria: women scheduled for attempted ECV with the fetal spine in the
midline (back-up or back-down) on US examination. N = 26. All women approached
agreed to participate.
Exclusion criteria: oligohydramnios (AFI < 5 cm), fetal or uterine anomalies, ruptured
amniotic membranes, active labour, engagement of presenting part, fetal heart rate de-
celerations
Interventions Intervention: vibroacoustic stimulation (B).
Fetal acoustic stimulation for 1 to 3 seconds with a Western Electric Division AT&T
(Phoenix) model 5C electrolarynx over the fetal head, or over the nurse’s upper arm
(dummy). Physician blinded by leaving the room during the intervention. N = 12
Comparison: placebo. N = 11.
Outcomes Persistent midline spine position on US (stimulation 1/13, control 13/13); failed ECV
attempt. Data on method of delivery not included because followed cross-over treatment
Notes 2 hospitals in Arizona, USA, 1 January 1993 to 31 December 1994
After randomisation, 1 from the treatment group and 2 from the control group were
excluded because the breech was found to be deeply engaged in the pelvis during the
initial ECV attempt. None had changed position to the spine lateral position, and no
further attempts at ECV were made. In keeping with the pre-stated protocol for this
review, these women have been included in the outcomes as originally allocated
Those women in whom ECV failed were crossed over to the other intervention arm.
This review considers only data from the first intervention, according to the original
allocation Results of the ’cross-over’ part of the study are not included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers.
Allocation concealment (selection bias) Low risk Selection of sequential envelopes generated
by a table of random numbers and handed
out by research nurse
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Clinicians were blinded, but the nurse ap-
plying the stimulation and the women
could not be blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Clinicians reported blinded, but the nurse
applying the stimulation and the women
could not be blinded
43Interventions for helping to turn term breech babies to head first presentation when using external cephalic version (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Johnson 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 women (12%) (1 treatment and 2 con-
trol) excluded, as breech was deeply en-
gaged. This loss should be insufficient to
affect the comparison
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk No baseline data are available for assess-
ment.
Kok 2008
Methods Multi-centre RCT.
Participants Inclusion criteria: term singleton, breech presentation pregnancies. GA of 36 weeks
onwards. N = 320.
Exclusion criteria: maternal exclusion: any contradiction to labour or vaginal birth,
scarred uterus other than transverse in the lower segment, known uterine anomalies,
placental abruption in the obstetric history, preeclampsia, maternal cardiac disease, third-
trimester bleeding. Fetal exclusion: IUGR (EFW < 5th percentile for GA assessed by
ultrasonography), fetal anomalies or an extended fetal head, oligohydramnios (defined
as an AFI ≤ 5 cm) and non-reassuring signs of fetal well-being
Interventions Intervention: tocolytic: nifedipine - calcium channel blocker (A2) - oral.
Nifedipine (2 doses of 10 mg) orally. N = 160 but 154 analysed
Comparison: placebo: placebo capsules. N = 160 but 156 analysed.
Outcomes Primary: successful ECV defined as a fetus in cephalic position 30 minutes after the ECV
procedure
Secondary: fetal presentation at birth, mode of birth and adverse maternal (major side ef-
fects due to medication, hypotension with fetal consequences, anaphylactic shock due to
the medication and any adverse cardiac events due to medication intake) and fetal events
(fetal death, emergency delivery, fetal bradycardia, premature rupture of the membranes
and placental abruption within 24 hours after the ECV procedure). Minor side effects:
nausea, dizziness and flushing and cessation of treatment because of side effects
Notes Nifedipine group - 2 women excluded as they were less than 39 weeks’ gestation, 2
excluded as they were repeat versions, 2 women lost to follow-up
Placebo group - 2 women excluded as they were less than 38 weeks, 2 excluded as they
were repeat versions
Study reports no events for fetal death; emergency delivery less than 24 hours; placental
abruption less than 24 hours; premature rupture of membranes less than 24 hours;
maternal hypotension with fetal consequences; anaphylactic shock
Risk of bias
Bias Authors’ judgement Support for judgement
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Kok 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Computer blocks of 10, stratified for centre and parity.
Allocation concealment (selection bias) Low risk Pharmacy prepared sealed opaque containers with study medi-
cation and kept an allocation list until completion of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded. All participants, nurses and doctors who per-
formed the ECV were blinded to the assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded. All participants, nurses and doctors who per-
formed the ECV were blinded to the assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 women were lost to follow-up or were excluded in the nifedip-
ine group, and 4 women in the control group
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk Baseline characteristics were similar. Baseline characteristics (Ta-
ble 1) indicate generally good balance, although there appears
to be some imbalance in placental anterior localisation (44 vs
55). Some imbalances were seen in some of the ethnicity data
(Central African (4 vs 10) and Other (18 vs 9)
Mancuso 2000
Methods RCT.
Participants Inclusion criteria: women undergoing ECV attempt. Age 18 years or greater, singleton
pregnancy, 37 weeks or more, breech or transverse presentation, intact membranes, EFW
2000 to 4000 g, reassuring fetal heart rate testing. N = 108
Exclusion criteria: placenta praevia, prior classical CS, third-trimester bleeding, AFI <
5 or > 25 cm, known uterine malformation, suspected major fetal anomaly, active-phase
labour
Interventions Intervention: regional analgesia (C) + tocolytic.
Lumbar epidural analgesia with 3 + 10 mL 2% lidocaine, with epinephrine test dose and
fentanyl 100 micrograms. N = 54
Comparison: no regional analgesia + tocolytic. N = 54.
All received Ringer’s Lactate 1500 mL IV, and terbutaline 0.25 mg SQ
Outcomes Presentation after ECV attempt; presentation at birth; fetal bradycardia causing cessation
of ECV attempts; the way women gave birth
Notes Tripler Army Medical Centre, Honolulu, Hawaii, December 1994 to June 1998
Risk of bias
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Mancuso 2000 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers table.
Allocation concealment (selection bias) Low risk ...with group assignments sealed in sequentially numbered
opaque envelopes randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It is not possible to blind people to epidurals.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It is not possible to blind people to epidurals.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions or loss to follow-up.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk Baseline data were similar between groups; no evidence of other
bias
Marquette 1996
Methods RCT.
Participants Inclusion criteria:women with singleton breech presentation, 36 to 41weeks’ gestation,
reactive CTG, breech mobile on abdominal palpation. N = 283
Exclusion criteria: impaired fetal growth (estimated weight < 10th percentile), oligohy-
dramnios (AFI < 5), placenta praevia, placental abruption, uterine scar other than low
transverse CS, active labour, ruptured membranes, fetal anomalies incompatible with
life, contraindication to vaginal delivery, contraindication to tocolysis
Interventions Intervention: tocolytic: ritodrine - beta stimulant (A1) - parenteral.
IVI, for 20 minutes before and during ECV attempt, of ritodrine 111 micrograms/
min or placebo. Maximum of 3 ECV attempts as forward or backward flip. CTG was
repeated. N = 138
Comparison: placebo. N = 145
Outcomes Duration of infusion (tocolysis mean 32.1 (SD 1.04) vs control 31.7 (1.12) minutes);
unsuccessful ECV; CTG results (all reactive); time from ECV to birth (average 2 weeks);
maternal and fetal complications (maternal complications < 4%, similar between groups)
; mode of birth; birthweight (3370 (39) vs 3382 (44) grams)
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Marquette 1996 (Continued)
Notes Groups differed in terms of frank breech (tocolysis 59/138 vs control 43/145) and
nulliparity (58/138 vs 49/145). Parity (nulliparous 34% vs parous 61%), but not type
of breech, affected ECV success rate; therefore results controlled for parity
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random assignment of every 10 patients enrolled: 5 to
ritodrine and 5 to control
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo and treatment made up in pharmacy in identical phials
and administered IV in the same solution at the same rate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo and treatment made up in pharmacy in identical phials
and administered IV in the same solution at the same rate
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions or loss to follow-up reported.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk Ritodrine group had higher proportion of nulliparous women.
It is unclear whether this would impact the comparison of out-
comes
Munoz 2014
Methods 2-arm RCT. Individual women randomly assigned.
Participants Dates of data collection: April 2010 to March 2011.
Setting: tertiary hospital in Spain with more than 3000 births a year
Inclusion criteria: women with non-cephalic presentation between 36 and 41 weeks’
gestation (All non-labouring pregnant women at 36 to 41 weeks’ gestation with a non-
cephalic presentation confirmed by ultrasound scan were invited to participate). N = 60
Exclusion criteria: fetal abnormalities, intrauterine fetal death, suspicion of fetal growth
restriction, fetal weight above 3800 g, maternal cardiovascular disease, American Society
of Anesthesiologists class > 2, severe hypertension, allergy to any trial medications, am-
niotic fluid index < 4 cm, Doppler cerebroplacental ratio > 5th percentile, abnormal car-
diotocographic recordings, contraindications to vaginal delivery, uterine abnormalities,
coagulation disorders, Rhesus incompatibility, multiple gestation, rupture of membranes
and/or placental abruption
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Munoz 2014 (Continued)
Interventions Experimental intervention: remifentanil.
Remifentanil at 0.1 lg/kg/min, with rescue boluses on demand of 0.1 lg/kg/min and a
lockout period of 4 minutes. Given by patient-controlled pump.All women given IV
infusion of ritodrine 200 lg/min for tocolysis. All women given 1 g paracetamol in 100
mL saline (IV) 5 minutes before ECV. N = 31
Control/Comparison intervention: placebo.
Study control solution at 0.1 lg/kg/min, with rescue boluses on demand of 0.1 lg/kg/
min and a lockout period of 4 minutes. Given by patient-controlled pump. All women
given IV infusion of ritodrine 200 lg/min for tocolysis. All women given 1 g paracetamol
(IV) 5 minutes before ECV. N = 29
Outcomes Pain score (numerical rating scale 0 to 10, no pain to worst pain imaginable); success of
ECV; CS; adverse events (nausea, vomiting, dizziness, etc); mode of birth; fetal brady-
cardia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “…computer-generated random
sequence…”.
Allocation concealment (selection bias) Low risk Hospital pharmacy prepared 100 mL in-
fusion bags that contained remifentanil (1
mg) or saline, which were labelled with the
patient code and sent to the operative room
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Women blind to allocation (placebo-con-
trolled trial).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Anaesthesiologists, midwives and obstetri-
cians were blinded to allocation group
Incomplete outcome data (attrition bias)
All outcomes
Low risk “After randomisation, three women were
excluded: two for spontaneous conversion
of the fetus to a cephalic presentation, and
one who declined to participate”
Obstetric data for 2 further women were
lost, but theywere included in the statistical
analysis on an intention-to-treat basis
Selective reporting (reporting bias) Low risk Trial registration form (Valero 2010) lists
outcomes, all of which were reported in
main study publication (Munoz 2014).
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Munoz 2014 (Continued)
Other bias Low risk No imbalance in age; BMI; estimated fetal
weight; ethnicity; parity; previous CS; pre-
sentation; placenta and amniotic fluid vol-
ume
Nor Azlin 2005
Methods RCT.
Participants Inclusion criteria: singleton term breech pregnancy at a tertiary hospital. N = 60.
Exclusion criteria: previous CS or other uterine scar, uterine malformation, antepartum
haemorrhage, hypertension, diabetes mellitus, IUGR, oligohydramnios, fetal anomalies,
early or active labour, contraindications to IV ritodrine, contraindication to vaginal
delivery
Interventions Intervention: tocolytic: ritodrine - beta stimulant (A1) - parenteral.
Ritodrine (IV) - 0.4 mg/mL in 5% dextrose infused at 1.5 mL/min. N = 30 (nulliparous
22 and multiparous 8)
Comparison: placebo. N = 30 (nulliparous 23 and multiparous 7).
Outcomes Successful ECV.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer random-number generator.
Allocation concealment (selection bias) Low risk Sealed numbered opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Obstetricians and women were blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Obstetricians and women were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions or incomplete data.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk More babies in the frank breech position in the ritodrine group
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Nor Azlin 2008
Methods RCT.
Participants Inclusion criteria: singleton term pregnancies with a breech presentation. N = 86.
Exclusion criteria: oligohydramnios, macrosomia, presence of a contraindication for
vaginal delivery, previous caesarean delivery, multiple pregnancy, hypertension in preg-
nancy, rhesus-negativemother, previous history of abruptio placenta, lethal fetal anomaly,
contraindication against nifedipine or terbutaline
Interventions Intervention: tocolytic: nifedipine - calcium channel blocker (A2) - oral.
Oral nifedipine (20 mg). N = 43 (nulliparous 18, multiparous 25)
Comparison: tocolytic: terbutaline - beta stimulant (A1) - parenteral.
IV terbutaline (50µg). N = 43 (nulliparous 21, multiparous 22) (6 lost to further follow-
up)
Outcomes Successful ECV, difficult ECV, palpitations, hypotension, method of delivery, perinatal
morbidity
Notes 6 successful ECVs from the terbutaline group were lost to follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random-number generator.
Allocation concealment (selection bias) Low risk Sealed, opaque, numbered envelopes in sequence.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Clinicians doing ECV were blinded to the tocolytic drug,
women were not blinded because 1 group had oral administra-
tion and the other IV. Clinicians doing the ECV were in control
of the success rate and were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Clinicians doing ECV were blinded to the tocolytic drug,
women were not blinded because 1 group had oral administra-
tion and the other IV. Clinicians doing the ECV were in control
of the success rate and were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Among those who had successful ECV, 6 from terbutaline group
were lost to follow-up, so although all women were included in
the assessment of the success of ECV, the outcome of CS is at
risk of bias
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk The study was not stopped early. Baseline characteristics were
similar between groups in maternal age, GA, AFI, parity and
type of breech presentation. No other biases were identified
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Reinhard 2012
Methods RCT comparing 2 interventions (clinical hypnosis or NLP) (a control group receiving
no intervention was used as a historical comparison - data for this group have not been
included in the review). Single-centre, stratified by parity
Participants Control group. From January 1, 2009, to October 31, 2010, a control group were all
ECVs, during which time neither hypnosis nor NLP was used. These data will not be
included
Setting: a tertiary university hospital in Germany. Johann Wolfgang Goethe University
Hospital in Frankfurt am Main
Inclusion criteria: pregnant women with a singleton fetus in a breech position at the
scheduled date of the ECV at or after 370/7 (259 days) weeks’ gestation, normal amniotic
fluid index, with advanced level of German language. N = 80
Exclusion criteria: women in active labour (regular uterine contractions and rupture of
membranes), contraindications for a vaginal birth (such as placenta praevia) and planned
birth by caesarean section even if the fetus turned to a cephalic position
Interventions Experimental intervention: hypnosis.
20-Minute standardized clinical hypnosis intervention via head phones (Bose, Quiet-
Comfort 15) before ECV procedure was carried out. Hypnosis intervention was a voice
recording of one of the trialists (a certified hypnotherapist who underwent training in
the fundamentals of NLP). A relaxation induction was utilised, in which the therapist
focused on breathing and concentrated on various parts of the body for trance deepening.
N = 42
Control/Comparison intervention: neurolinguistic programming.
20-Minute standardised NLP intervention via head phones (Bose, QuietComfort 15)
before ECV procedure was carried out. Hypnosis intervention was a voice recording of
1 of the trialists (a certified hypnotherapist who underwent training in the fundamentals
of NLP). N = 38
Outcomes ECV success; women’s views (results reported asmeans derived fromLikert 6-point scale)
Notes We contacted the study author for more information re the NLP intervention and
received additional information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Off-centre randomisation sequence based
on block randomisation was calculated and
assigned by the Institute of Biostatistics and
Mathematical Modeling
Allocation concealment (selection bias) Unclear risk Allocation at the point of randomisation
was not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Intervention was double-blinded, that is,
the participant and the clinician who car-
ried out the ECV procedure did not know
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Reinhard 2012 (Continued)
the kind of intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Intervention was double-blinded, that is,
the participant and the clinician who car-
ried out the ECV procedure did not know
the kind of intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up evident after randomi-
sation.
Selective reporting (reporting bias) Unclear risk We did not assess trial protocol.
Other bias Low risk Other bias not apparent.
Robertson 1987
Methods Quasi-RCT
Participants Inclusion criteria: breech presentation suitable for ECV at term (37 to 41 weeks). N =
58
Exclusion criteria: oligohydramnios, estimated fetal weight < 2500 g or > 4000 g, non-
reactive NST
Interventions Intervention: tocolytic: ritodrine - beta stimulant (A1) - parenteral.
Use of tocolysis (ritodrine infusion200microgramsperminute for 20minutes) compared
with no tocolysis. All women had IV lines. Repeat version attempt with tocolysis was
successful in 1/9, with initial failure in the control group (for immediate success rate,
this review considered only the initial attempt). N = 30
Comparison: no tocolytic. N = 28.
Outcomes Non-cephalic presentation at birth; CS; immediate ECV success
Notes Tacoma, Washington, USA. July 1984 to May 1987.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Allocated according to last digit of social security number.
Allocation concealment (selection bias) High risk Allocated according to last digit of social security number.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
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Robertson 1987 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 women lost to follow-up in the intervention group and 5 in
the control group. This seems unlikely to impact outcomes
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk Groups were similar in age, parity, maternal weight, GA, EFW.
No other biases apparent
Schorr 1997
Methods RCT.
Participants Inclusion criteria: breech presentation or transverse lie. N = 69.
Exclusion criteria: placenta praevia, fetal compromise, fetal growth restriction, ruptured
membranes
Interventions Intervention: regional analgesia (C) + tocolytic.
Epidural analgesiawith 2% lidocainewith 1:200,000 epinephrine (N=35); prehydration
with 2000 mL lactated Ringer’s solution vs no epidural (N = 34). All women received
0.25 mg terbutaline SQ. ECV attempted up to 3 times, with vaginal elevation of the
presenting part when necessary. N = 35
Comparison: no regional analgesia + tocolytic. N = 34.
250 mg terbutaline given as adjunct.
Outcomes Successful ECV, complications, mode of birth, presentation at delivery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation cards placed in permuted
blocks of 10 by Division of Biostatistics
Allocation concealment (selection bias) Low risk Allocation put in sealed opaque envelopes, and all investigators
participating in clinical aspects of the study were blinded to the
randomisation sequence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It is not possible to blind people to the use of epidurals.
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Schorr 1997 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It is not possible to blind people to the use of epidurals.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although 5 women declined randomisation, there seemed to be
no exclusions and no loss to follow-up
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk No differences in baseline data. No other biases apparent.
Stock 1993
Methods RCT.
Participants Inclusion criteria: breech presentation between 36 and 42 weeks with no contraindica-
tion to ECV. N = 63.
Exclusion criteria:diabetes, heart disease, thyrotoxicosis, rupturedmembranes,multiple
pregnancy, uterine scar, placenta praevia, oligohydramnios, impaired fetal growth, nuchal
cord, placenta praevia
Interventions Intervention 1: tocolytic: ritodrine - beta stimulant (A1) - parenteral.
Group B: ritodrine 0.3mg perminute infusion for 30minutes and during the procedure,
and placebo bolus injection. N = 21
Intervention 2: tocolytic: hexoprenaline - beta stimulant (A1) - parenteral.
Group C: placebo infusion and hexoprenaline 10 micrograms bolus injection. N = 21
Comparison: placebo.
Group A: placebo infusion and bolus injection. N = 21.
For the purposes of this review, which addresses the effectiveness of IV tocolysis for
ECV rather than the evaluation of specific tocolytic agents, intervention 1 (group B)
and intervention 2 (group C) have been combined
Nulliparous = 18 in tocolytic groups and 9 in placebo group.
Multiparous = 24 in tocolytic groups and 12 in placebo group
We have not set up a subgroup comparison of 1 beta stimulant vs another, so the data
from this study on failed ECV for ritodrine (7/21) vs hexoprenaline (5/21) are not
included as a direct comparison
Outcomes Immediate ECV success; ECV completed < 1 minute; fetal bradycardia during ECV
Notes Improved ECV success rate with tocolysis reached statistical significance for hexopre-
naline but not for ritodrine. Study authors decided not to continue the ritodrine/placebo
arm of the trial to completion
Risk of bias
Bias Authors’ judgement Support for judgement
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Stock 1993 (Continued)
Random sequence generation (selection
bias)
Unclear risk ’Each investigator had a separate randomisation sequence. These
were in sets of 3 to the 3 groups, stratified for parity.’ Method
of randomisation not specified
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial. Practitioners were blind to group allo-
cation, as were the women
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Practitioners were blind to group allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of exclusions of loss to follow-up.
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias High risk No statistically significant differences between groups in terms
of parity, height, age or gestation at time of ECV (see Table 2
on page 266). No differences between groups regarding fetal
biparietal diameter, abdominal circumference. Femur length or
AFI. Women in ritodrine group were significantly lighter than
those in the other 2 groups
Trial stopped early for benefit.
Sullivan 2009
Methods RCT.
Participants Inclusion criteria: singleton breech presentations after 36 weeks’ gestation. N = 95.
Exclusion criteria: patients with contraindications to neuraxial anaesthesia, allergies to
study medications
Interventions Intervention: systemic opioids (E) + tocolytic.
Systemic opioids (50 µg fentanyl). N = 47.
Comparison: regional analgesia (C) + tocolytic.
CSE anaesthesia (bupivacaine 2.5 mg and 15 µg fentanyl followed by 45 mg lidocaine
and 15 µg epinephrine). N = 48
Both groups received terbutaline.
Outcomes Successful ECV, hypotension, decelerations of FHR, persistent decelerations, CS
Notes 1 woman excluded after randomisation before ECV because of non-reassuring CTG
Risk of bias
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Sullivan 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer random-number table.
Allocation concealment (selection bias) Low risk Sequentially numbered opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman was excluded after randomisation because she under-
went an emergency CS. Other possible exclusions are unclear
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk No significant differences between the 2 groups in age, parity,
GA, height, weight or obstetricianpredicted difficulty of version.
Other biases not identified
Tan 1989
Methods RCT.
Participants Inclusion criteria: breech presentation beyond 33 weeks’ gestation without contraindi-
cation to ECV. N = 90.
Exclusion criteria: signs of growth restriction, vaginal bleeding in the third trimester,
toxaemia of pregnancy, labour, polyhydramnios, placenta praevia, previous CS scar, con-
tracted pelvis, fetal malformation and uterine malformation
Interventions Intervention 1: tocolytic: salbutamol - beta stimulant (A1) - parenteral.
Group 2 received an IVI of salbutamol until maternal heart rate exceeded 100 beats per
minute for 30 minutes. N = 30 (nulliparous 17, multiparous 13)
Intervention 2: tocolytic: salbutamol - beta stimulant (A1) - oral.
Group 1 received salbutamol 4 mg orally 3 times a day for at least 1 day. N = 30
(nulliparous 16, multiparous 14)
Comparison: placebo.
Group 3 received no salbutamol. N = 30 (nulliparous 17, multiparous 13)
Groups 1 and 3 received dummy IV lines
Outcomes Immediate ECV success.
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Tan 1989 (Continued)
Notes Singapore.
This study compared 2 different routes of administration (oral and IV) of a tocolytic
drug to facilitate ECV. So it provides data only for tocolysis vs placebo, and the different
routes of administration are considered in subgroups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided.
Allocation concealment (selection bias) High risk 2 stacks of randomised cards divided according to parity with
each stack further subdivided by a colour code for gestation A
or B
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States that clinicians were blinded to treatment and dummy
IVs were inserted. Clinicians did not know parity or gestation.
Women’s status unclear, but clinicians more likely to be able to
influence outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk States that clinicians were blinded to treatment and dummy
IVs were inserted. Clinicians did not know parity or gestation.
Women’s status unclear, but clinicians more likely to be able to
influence outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions apparent after randomisation and no loss to fol-
low-up
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk The 3 groups were similar in placental site, abdominal girth,
maternal weight, fetal birthweight and stratification of parity
and gestation across groups
Failed ECV: Time taken was significantly longer (10.5 + 4.9 vs
5.6 + 3.9; P value < 0.001) and onset of labour was significantly
earlier (17.6 + 9.8 vs 25.2 + 14.9 days; P value < 0.02), implying
that longer manipulation hastened the onset of labour by 70%
Vallikkannu 2014
Methods RCT 2-arm (then cross-over for second attempt; data following cross-over have not been
included in the review)
Participants Dates of data collection: 18 Jan 2011 to 23 Dec 2012.
Setting: University Hospital, Kuala Lumpur, Malaysia. 6000 to 7000 births a year
Inclusion criteria: women scheduled for ECV (≥ 36 weeks’ gestation).
Scheduled ECV, breech presentation or transverse lie, singleton gestation, gestational
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Vallikkannu 2014 (Continued)
age ≥ 36 weeks, intact membranes, non-anomalous fetus, reassuring fetal status on
cardiotocogram. N = 95
Exclusion criteria: regular contractions were present, estimated fetal weight < 2 kg,
oligohydramnios (amniotic fluid index < 5 cm), severe hypertension, recent antepartum
haemorrhage, uterine scar, related allergy and any potential contraindication to vaginal
birth
Interventions Experimental intervention: powder.
Commercially available baby talcum powder was applied to the woman’s abdomen by
the operator. N = 48
250 mcg terbutaline was administered subcutaneously 5 to 10 minutes before ECV was
attempted
In the first round, a maximum of 2 attempts at ECV were permitted. An attempt
comprised a continuous manoeuvre typically lasting not longer than 2 to 3minutes. Fetal
presentation and heart rate were then checked by ultrasound. If ECV was unsuccessful
but fetal heart rate was normal and the woman was agreeable, a second attempt was
made with the same allocated aid. After completion of the first round of a maximum
of 2 attempts, the participant was asked to record her ECV-related pain score, and the
operator was asked to provide a satisfaction score with use of the allocated aid, using a
10 point visual numerical rating scale (VNRS - scored from 1 to 10, marked as higher
score more desirable result)
Following an unsuccessful first round of ECV, if fetal status was reassuring on car-
diotocogram (i.e. until at least 2 fetal heart rate accelerations were observed in the con-
text of a normal baseline, baseline variability and absence of decelerations), and both
the provider and the woman were willing, a second round of up to 2 ECV attempts
was permitted with cross-over to the opposing aid, i.e. powder to gel, gel to powder. A
further terbutaline dose was given for the second round, which was conducted in similar
fashion to the first round
Control/Comparison intervention: gel.
Ultrasound aqueous gel was applied to the woman’s abdomen by the operator. N = 47
250 mcg terbutaline was administered subcutaneously 5 to 10 minutes before ECV was
attempted
In the first round, a maximum of 2 attempts at ECV were permitted. An attempt
comprised a continuous manoeuvre typically lasting not longer than 2 to 3minutes. Fetal
presentation and heart rate were then checked by ultrasound. If ECV was unsuccessful
but fetal heart rate was normal and the woman was agreeable, a second attempt was
made with the same allocated aid. After completion of the first round of a maximum
of 2 attempts, the participant was asked to record her ECV-related pain score, and the
operator was asked to provide a satisfaction score with use of the allocated aid, using a
10 point visual numerical rating scale (VNRS - scored from 1 to 10, marked as higher
score more desirable result)
Following an unsuccessful first round of ECV, if fetal status was reassuring on car-
diotocogram (i.e. until at least 2 fetal heart rate accelerations were observed in the con-
text of a normal baseline, baseline variability and absence of decelerations), and both
the provider and the woman were willing, a second round of up to 2 ECV attempts
was permitted with cross-over to the opposing aid, i.e. powder to gel, gel to powder. A
further terbutaline dose was given for the second round, which was conducted in similar
fashion to the first round
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Vallikkannu 2014 (Continued)
Outcomes Self-reported pain; success of ECV; operator’s VNRS satisfaction score (identical scale
to the pain VNRS described above) with the agent used; significant post-ECV car-
diotocogram anomaly; cephalic presentation at birth; caesarean (and indication); neona-
tal outcomes of Apgar score, umbilical cord arterial blood pH and base deficit and neona-
tal admission; gestational age at birth; blood loss at birth and birthweight; fetal or neona-
tal death; neonatal hypoxic-ischaemic encephalopathy and major abruptio placenta
ECV was considered a success if cephalic presentation was demonstrated on ultrasound
immediately after an attempt
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “…computer generated randomisation se-
quence obtained from http://www.ran-
dom.org...”
Allocation concealment (selection bias) Unclear risk “…randomisation envelopes were prepared
by an author (NV who was not involved in
recruitment) in a single block of 100…se-
quential opening of the lowest numbered
sealed opaque envelope remaining just be-
fore the start of ECV”
5 envelopes were not accounted for.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Blinding of providers and patients to the
intervention was not attempted as it was
considered unachievable.” It was not clear
whether staff were using their usual or pre-
ferred method (it was stated that talcum
powder had mainly been used, although
some staff had started to use gel for ECV)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding was not attempted, as it was con-
sidered unachievable
Incomplete outcome data (attrition bias)
All outcomes
Low risk 48 randomly assigned to powder and 47 to
gel. Recruitment ceased when all 100 num-
bered envelopes were used. 5 numbered en-
velopes could not be accounted for (2 allo-
cated to powder and 3 allocated to gel). All
participants received powder or gel as allo-
cated for their first round of ECV. Primary
analysis was per protocol
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Vallikkannu 2014 (Continued)
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk No baseline imbalances in age; gestation;
parity; nulliparous; weight; height; BMI;
ethnicity; etc.When possible, we have used
the data related to the first attempt only, but
the assessment of pain seems to be pooled
in the published paper
Vani 2009
Methods RCT.
Participants Inclusion criteria:healthywomen, singleton fetus in breech presentation, 37 to 39weeks
with intactmembranes, no signs of labour and a clinically EFW2 to 4 kg.USS performed
to confirm breech presentation and to ascertain fetal neck position and location of the
placenta. N = 114
Exclusion criteria: AFI outside range of 5 to 25, fetal hyperextended neck, placenta pre-
via, gross fetal anomalies, hypertension, gestational diabetes, antepartum haemorrhage,
uterine scar (from CS, myomectomy or perforation), uterine malformation allergy or
contraindication to salbutamol or contraindication to a trial of labour even if in cephalic
presentation
Interventions Intervention: tocolytic: salbutamol - beta stimulant (A1) - parenteral.
Salbutamol (IV dose of 0.1 mg salbutamol with further boluses every 5 minutes). N =
57
Comparison: placebo. N = 57.
Outcomes Successful ECV, palpitations, hypotension, fetal presentation at delivery, method of
delivery, perinatal morbidity, Apgar scores
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generated by a random-number generator.
Allocation concealment (selection bias) Low risk Sealed numbered opaque envelopes prepared in blocks of 4.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label RCT and IV administration of tocolytic was not
blinded
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Vani 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label RCT and IV administration of tocolytic was not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions after randomisation and no loss to follow-up. All
women received their allocated treatment
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk A significant difference was noted in the location of the placenta
between the 2 groups. Significantly more women in the tocolysis
grouphad a placenta attached to the fundus. Fewerwomen in the
intervention group had a placenta in the anterior upper segment
and more in the posterior upper segment, although statistical
significance is not reported. It is unclear whether this would have
an impact on outcomes
Post hoc multivariate logistic regression analyses incorporating
placental location and allocated treatment as independent co-
variables in the analysis with successful ECV and CS reported
separately as dependent outcomes. After control for placental
location in both models for successful ECV and CS salbutamol,
tocolysis remained significantly associated with increased ECV
success (adjusted OR 3.4; 95% CI 1.4 to 8.2; decreased CS
adjusted OR 3.4; 95% CI 0.14 to 0.79)
Weiniger 2007
Methods RCT.
Participants Inclusion criteria: All eligible nulliparous women who requested ECV after 37 weeks’
gestation during the period from September 2002 to May 2006 were approached for
recruitment before the ECV procedure. Inclusion criteria included American Society of
Anesthetists status I to II at 37 to 40 weeks’ gestation, and no fetal abnormality. N = 70
Exclusion criteria: women with a breech presenting fetus who requested elective cae-
sarean delivery, either after failed ECV at another institution or because they did not wish
to try ECV at all, were not included or followed up, and data regarding these women
were not collected. Women with any of the following were excluded: previous uterine
surgery or uterine anomaly, contraindication for vaginal delivery, contraindications for
regional analgesia, woman’s refusal of regional analgesia, neuropathy, severe back pain
with neurological radiation, poor communication and morbid obesity (body mass index
> 40 kg/m2).
Interventions Intervention: regional analgesia (C) + tocolytic.
Spinal analgesia (bupivacaine 7.5 mg). N = 36.
Comparison: no regional analgesia + tocolytic. N = 34.
Both groups received 50 mg ritodrine or 20 mg nifedipine sublingually
Outcomes Successful ECV.
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Weiniger 2007 (Continued)
Notes In spinal group: 1 woman excluded as morbidly obese, 1 women requested to not have
spinal after randomisation
In placebo group: 1 woman excluded as morbidly obese, 1 refused ECV after randomi-
sation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation cards randomly inserted into envelopes by a physician
not involved in the study
Allocation concealment (selection bias) Unclear risk Study allocation was by sequentially numbered sealed envelopes
containing a concealed allocation card designating the partici-
pant to receive (group S), or not receive (group N), spinal anal-
gesia. Allocation sequence was concealed until after enrolment,
and informed consent was obtained before study assignment of
the participant was revealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It is not possible to blind people to regional analgesia.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It is not possible to blind people to regional analgesia.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women in each group were excluded from the analysis (1 in
each group declined ECV or the intervention, and 1 protocol
violation was reported in each group). This was considered in-
sufficient to impact the analysis
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk Women in the intervention group were significantly younger
than those in the control group, but other baseline characteris-
tics were similar between groups (height, weight, weight gain,
EFW, GA, amniotic fluid volume, placental position, fetal pre-
sentation, position of fetal spine, tocolytic used)
Weiniger 2010
Methods RCT.
Participants Inclusion criteria:Healthy multiparae at term requesting ECV for breech presentation,
without fetal or uterine anomaly, were enrolled after written informed consent, and
all eligible multiparae requesting ECV after 37 weeks’ gestation were approached for
recruitment before the ECV. ASA status I to II, 37 to 40 complete weeks’ gestation,
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Weiniger 2010 (Continued)
no fetal abnormality (including IUGR), no contraindication for vaginal delivery or no
contraindication for regional analgesia. N = 64
Exclusion criteria: previous CS, previous myomectomy with uterine cavity penetration
or uterine anomaly, morbid obesity (body mass index 40 kg/m2), AFI 7 cm, neuropathy,
severe back pain with radicular radiation, patient refusal of regional analgesia, poor
communication or request for elective CS (after failed ECV at another institution or not
wishing to attempt ECV)
Interventions Intervention: regional analgesia (C) + tocolytic.
Spinal analgesia (bupivacaine 7.5 mg). N = 31.
Comparison: no regional analgesia + tocolytic. N = 33.
Ritodrine (50 mg IV) used as muscle relaxant until April 2003, when it was replaced by
nifedipine (20 mg orally)
Outcomes Successful ECV.
Notes 1 woman’s data not analysed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...concealed cards allocated at random by a physician not in-
volved in study enrolment...”
Allocation concealment (selection bias) Unclear risk “Women were randomised using numbered sealed envelopes
containing concealed cards allocated at random by a physician
not involved in study enrolment”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The 2 experienced ECV-performing obstetricians were not
blinded. Women could not be blinded either
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding attempted
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman (in analgesia group) refused ECV after randomisation.
1 woman randomly assigned to receive spinal analgesia did not
receive the intended treatment, as the anaesthetist was unable to
locate the dura (her ECVwas unsuccessful, but she was analysed
as intention-to-treat in the spinal analgesia group)
2 women with breech presentation in consecutive pregnancies
were enrolled twice in the current study. A further analysis with-
out these women was performed to exclude potential bias for
the primary outcome. The success of ECV with spinal analgesia
excluding the repeat data was 23 of 27 (85.1%) vs 19 of 33 (57.
5%) without analgesia (P value < 0.02)
None of thiswould be sufficient to have an impact on the analysis
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Weiniger 2010 (Continued)
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Unclear risk Similar maternal age, GA, weight at time of ECV and height.
Similar too in terms of breech in past pregnancy, EFW, AFI.
Study authors report there was no difference according to parity
in the rate of successful ECV within intention-to-treat groups.
However, it should be noted that for parity 1, 13 were included
in the spinal analgesia group and 21 in the no analgesia group
Yanny 2000
Methods RCT.
Participants Inclusion criteria: women with breech presentation choosing ECV, cardiotocograph
and US examination acceptable, failed initial ECV attempt without tocolysis. N = 57
Interventions Intervention: tocolytic: glycerol trinitrate/nitroglycerine - nitric oxide donor (A3) -
sublingual
Glyceryl trinitrate sublingual spray 800 µg. N = 31.
Comparison: placebo. N = 26.
Labelled sprays A and B; repeat ECV attempt; if unsuccessful and uterus not relaxed,
salbutamol infusion and repeat ECV attempt
Outcomes Side effects: maternal discomfort; blood pressure; pulse, after spray administration; ECV
success; uterine relaxation (poor 8/30 nitroglycerine vs 9/25 placebo, reasonable 11/30
vs 8/25, good 7/30 vs 8/25, excellent 4/30 vs 0/25); salbutamol required (13/31 vs 14/
26); dose of salbutamol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers.
Allocation concealment (selection bias) Low risk Used opaque sealed envelopes, but no information as to whether
they were sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
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Yanny 2000 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions were reported after randomisation, and no loss to
follow-up
Selective reporting (reporting bias) Unclear risk We did not assess the trial protocol.
Other bias Low risk Baseline characteristics for thewomenwere similar between the 2
groups in maternal age, parity, extended legs and liquor volume.
No other biases were apparent
AFI: amniotic fluid index.
BMI: body mass index.
CI: confidence interval.
CS: caesarean section.
CSE: combined spinal epidural.
CTG: cardiotocography.
ECV: external cephalic version.
EFW estimated fetal weight.
GA: gestational age.
IUGR: intrauterine growth restriction.
IV: intravenous.
IVI: intravenous infusion.
min(s): minute(s).
NST: non-stress test.
OR: odds ratio.
RCT: randomised controlled trial.
SD: standard deviation.
SQ: subcutaneous.
US: ultrasound.
vs: versus.
A: Tocolytic drugs: A1 - beta stimulants; A2 - calcium channel blockers; A3 - nitric oxide donors.
B: Vibroacoustic stimulation.
C: Regional analgesia.
D: Amnioinfusion.
E: Systemic opioids.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dockeray 1984 Non-randomised follow-up study comparing outcomes of patients who had an ECV vs patients who had a breech
vaginal delivery
Guittier 2013 This was not a randomised trial. 63 women undergoing ECV under hypnosis between 2010 and 2013 were
compared with 122 women receiving standard care between 2005 and 2008
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(Continued)
Wallace 1984 Non-randomised follow-up study after randomised trial of ECV with tocolysis
ECV: external cephalic version.
Characteristics of studies awaiting assessment [ordered by study ID]
Andarsio 2000
Methods RCT.
Participants Inclusion criteria: women undergoing ECV attempt. Unit: individual women. N = 35 women included
Interventions Intervention: tocolysis: nitroglycerine - nitric oxide donor (A3) - no route reported
Nitroglycerine: only abstract available, no dose or route of administration given. N = 18
Comparison: tocolysis: terbutaline - beta stimulant (A1) - no route reported.
Terbutaline: only abstract available, no dose or route of administration given. N = 17
Outcomes ECV success.
Notes Preliminary abstract report only reviewed. This study was included in the previous publication (Cluver 2012), but
we cannot include in this update until we have information on the routes of administration used. We are writing to
study authors to request this information
Hollard 2003
Methods RCT.
Participants Inclusion criteria: normal singleton breech pregnancy, gestational age 36 weeks or more, intact membranes, not in
labour. N = 36
Interventions Intervention: regional analgesia (C).
1000 mL IVI prehydration and intrathecal injection of 6 mg 2% lidocaine with 15 mcg fentanyl. Followed by the
same protocol as comparison group. N = 19
Comparison: no regional analgesia + tocolytic.
0.25 mg SQ terbutaline and ECV attempted by a MFM physician. N = 17
Outcomes Maternal pain (reduced in spinal analgesia group) and satisfaction (no difference) on visual scale; ECV success
Notes January 1998 to January 2003.
It is unclear whether both groups received terbutaline or just the comparison group. We are writing to study authors
to clarify this and other details of the study
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Tan 2008
Methods Double-blind RCT.
Participants Womenwith a singleton baby in the breech position.Gestation≥ 36weeks (check for early confirmation of gestational
age), intact membranes and assuring fetal status on cardiotocograph. N = at least 103 women
Interventions 250 µg or 500 µg of bolus subcutaneous terbutaline followed by ECV 15minutes later with a maximum of 2 attempts
Outcomes Primary: immediate success rate of ECV; caesarean section; cephalic presentation at birth
Secondary: post-ECVcardiotocograph abnormalities; neonatal nursery admission; Apgar score at 5minutes; umbilical
cord arterial blood, pH; adverse drug events; visual analogue scale satisfaction score with ECV; indication for operative
delivery
Notes Study reported as completed, but no information or data available as yet
ECV: external cephalic version.
IVI: intravenous infusion.
RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Burgos 2012
Trial name or title Open randomised controlled trial to evaluate the efficacy and safety of remifentanil versus nitrous oxide in
external cephalic version at term in singleton pregnancy in breech presentation (REMIVER)
Methods Single-centre randomised parallel-group controlled trial. Analysis by intention-to-treat
Participants Women 18 to 65 with term pregnancy, singleton pregnancy in breech position (estimated enrolment: 180
women). Setting: hospital in Spain
Interventions Remifentanil vs inhaled nitrous oxide.
Outcomes Rate of successful ECV, analgesic effect, safety, caesarean rates, acceptability of procedures to the women
Starting date July 2012 (expected final data collection date: July 2013).
Contact information Jorge Burgos, jburgoss@sego.es
Notes
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Passerini 2013
Trial name or title Maternal oral hydration and external cephalic version.
Methods Randomised trial.
Participants 164 pregnant women over 18 years of age with breech presentation at term
Interventions Women in the intervention will be asked to drink 2 litres of water in 2 hours; the control group will receive
no intervention
Outcomes Successful external cephalic version, amniotic fluid volume, type of birth
Starting date October 2011 (expected final data collection date: January 2014)
Contact information virna.zobbi@unimib.it
Notes
ECV: external cephalic version.
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D A T A A N D A N A L Y S E S
Comparison 1. Tocolytic drugs (A) vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Beta stimulants -
parenteral
5 459 Risk Ratio (M-H, Random, 95% CI) 1.68 [1.14, 2.48]
1.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Calcium channel blockers
- oral or sublingual
1 310 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.87, 1.48]
1.4 Nitric oxide donors -
parenteral
1 125 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.91, 2.76]
1.5 Nitric oxide donors - oral
or sublingual
1 99 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.52, 1.05]
2 Failure to achieve cephalic
vaginal birth (composite
outcome: caesarean section +
vaginal breech birth)
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Beta stimulants -
parenteral
4 399 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.60, 0.92]
2.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Calcium channel blockers
- oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Nitric oxide donors - oral
or sublingual
1 99 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.86, 1.72]
3 Caesarean section (primary) 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Beta stimulants -
parenteral
6 742 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.67, 0.88]
3.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Calcium channel blockers
- oral or sublingual
1 310 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.88, 1.40]
3.4 Nitric oxide donors -
parenteral
1 125 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.67, 1.02]
3.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Fetal bradycardia (primary) 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Beta stimulants -
parenteral
1 58 Risk Ratio (M-H, Random, 95% CI) 2.81 [0.12, 66.17]
4.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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4.3 Calcium channel blockers
- oral or sublingual
1 310 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.50, 2.43]
4.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Nitric oxide donors - oral
or sublingual
1 99 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.93]
5 Failed external cephalic version 13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Beta stimulants -
parenteral
9 900 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.60, 0.82]
5.2 Beta stimulants - oral or
sublingual
1 45 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.56, 1.79]
5.3 Calcium channel blockers
- oral or sublingual
1 310 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.78, 1.11]
5.4 Nitric oxide donors -
parenteral
1 126 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.70, 1.06]
5.5 Nitric oxide donors - oral
or sublingual
2 156 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.55, 1.96]
6 Difficult external cephalic
version
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Beta stimulants -
parenteral
1 63 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.16, 1.54]
6.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Calcium channel blockers
- oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Maternal palpitations 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Beta stimulants -
parenteral
1 114 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.25, 101.89]
7.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Calcium channel blockers
- oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Nitric oxide donors -
parenteral
1 117 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.05, 5.27]
7.5 Nitric oxide donors - oral
or sublingual
1 99 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Maternal headaches 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Beta stimulants -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Calcium channel blockers
- oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.4 Nitric oxide donors -
parenteral
1 117 Risk Ratio (M-H, Random, 95% CI) 18.68 [1.11, 313.77]
8.5 Nitric oxide donors - oral
or sublingual
1 99 Risk Ratio (M-H, Random, 95% CI) 10.29 [2.55, 41.56]
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9 Maternal hypotension 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Beta stimulants -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Calcium channel blockers
- oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.4 Nitric oxide donors -
parenteral
1 117 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.26, 8.50]
9.5 Nitric oxide donors - oral
or sublingual
1 99 Risk Ratio (M-H, Random, 95% CI) 5.88 [0.73, 47.07]
10 Operative vaginal birth 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Beta stimulants -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Calcium channel
blockers - oral or sublingual
1 310 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.09, 1.22]
10.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Maternal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Beta stimulants -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.3 Calcium channel
blockers - oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Maternal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Beta stimulants -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.3 Calcium channel
blockers - oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Perinatal mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 Beta stimulants -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.3 Calcium channel
blockers - oral or sublingual
1 310 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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13.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14 Perinatal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Beta stimulants -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.3 Calcium channel
blockers - oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15 Vaginal breech birth 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Beta stimulants -
parenteral
1 124 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.30, 3.28]
15.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.3 Calcium channel
blockers - oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16 Apgar < 7 at 5 minutes (not
prespecified)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 Beta stimulants -
parenteral
2 227 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.3 Calcium channel
blockers - oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17 Neonatal seizures (not
prespecified)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 Beta stimulants -
parenteral
1 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.3 Calcium channel
blockers - oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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18 Admission to neonatal unit
(not prespecified)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 Beta stimulants -
parenteral
2 238 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.30, 3.36]
18.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18.3 Calcium channel
blockers - oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 Birth trauma (not prespecified) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 Beta stimulants -
parenteral
1 114 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 Calcium channel
blockers - oral or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal flushing (not
prespecified)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 Beta stimulants -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Beta stimulants - oral or
sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Calcium channel
blockers - oral or sublingual
1 310 Risk Ratio (M-H, Random, 95% CI) 23.30 [1.38, 391.91]
20.4 Nitric oxide donors -
parenteral
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.5 Nitric oxide donors - oral
or sublingual
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
1 90 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.39, 0.98]
1.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
1 74 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.29, 1.09]
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1.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Failure to achieve cephalic
vaginal birth (composite
outcome: caesarean section +
vaginal breech birth)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
1 74 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.88, 1.47]
2.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Caesarean section (primary) 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
2 170 Risk Ratio (M-H, Random, 95% CI) 1.28 [1.03, 1.59]
3.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Fetal bradycardia (primary) 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
2 170 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.46, 3.03]
4.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
1 74 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.16, 7.10]
4.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Failed external cephalic version 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
2 176 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.06, 1.86]
5.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
2 133 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.13, 1.94]
5.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Difficult external cephalic
version
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
1 90 Risk Ratio (M-H, Random, 95% CI) 5.22 [0.26, 105.81]
6.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Maternal palpitations 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
1 86 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.23, 2.78]
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7.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
1 74 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.10, 2.71]
7.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Maternal headaches 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
1 74 Risk Ratio (M-H, Random, 95% CI) 3.52 [1.05, 11.76]
8.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Maternal hypotension 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Calcium channel blockers
(A2) vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
1 74 Risk Ratio (M-H, Random, 95% CI) 3.17 [0.35, 29.06]
9.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Operative vaginal birth 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Maternal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Maternal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Perinatal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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13.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14 Perinatal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15 Vaginal breech birth (not
prespecified)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16 Apgar < 7 at 5 minutes (not
prespecified)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
1 89 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17 Neonatal seizures (not
prespecified)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 Admissions to neonatal unit
(not prespecified)
1 86 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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18.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
1 86 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 Birth trauma (not prespecified) 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20 Maternal flushing (not
prespecified)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 Calcium channel
blockers (A2) vs beta stimulants
(A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Nitric oxide donors (A3)
vs beta stimulants (A1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Nitric oxide donors (A3)
vs calcium channel blockers
(A2)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Vibroacoustic stimulation (B) vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Failure to achieve cephalic
vaginal birth (composite
outcome: caesarean section +
vaginal breech birth)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Caesarean section (primary) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Fetal bradycardia (primary) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Failed external cephalic version 1 23 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 0.60]
6 Difficult external cephalic
version
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Maternal palpitations 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Maternal headaches 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Maternal hypotension 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Operative vaginal birth 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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12 Maternal morbidity 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Perinatal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14 Perinatal morbidity 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Regional analgesia (with or without tocolysis) vs no intervention of regional analgesia (with or
without tocolysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Regional analgesia +
tocolysis vs tocolysis
3 279 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.78, 2.66]
2 Failure to achieve cephalic
vaginal birth (composite
outcome: caesarean section +
vaginal breech birth)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Caesarean section (primary) 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Regional analgesia +
tocolysis vs tocolysis
3 279 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.40, 1.37]
4 Fetal bradycardia (primary) 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Regional analgesia +
tocolysis vs tocolysis
2 210 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.62, 3.57]
5 Failed external cephalic version 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Regional analgesia alone
vs no intervention
1 141 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.70, 1.14]
5.2 Regional analgesia +
tocolysis vs tocolysis
5 409 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.43, 0.86]
6 Difficult external cephalic
version
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Regional analgesia +
tocolysis vs tocolysis
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Maternal palpitations 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Regional analgesia +
tocolysis vs tocolysis
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Maternal headaches 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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8.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Regional analgesia +
tocolysis vs tocolysis
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Maternal hypotension 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Regional analgesia +
tocolysis vs tocolysis
3 280 Risk Ratio (M-H, Random, 95% CI) 11.58 [1.53, 87.50]
10 Operative vaginal birth 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Regional analgesia +
tocolysis vs tocolysis
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Maternal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Regional analgesia +
tocolysis vs tocolysis
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Maternal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Regional analgesia +
tocolysis vs tocolysis
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Perinatal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Regional analgesia +
tocolysis vs tocolysis
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14 Perinatal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Regional analgesia +
tocolysis vs tocolysis
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15 Placental abruption (not
prespecified)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Regional analgesia +
tocolysis vs tocolysis
1 102 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.31]
16 Maternal discomfort (not
prespecified)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 Regional analgesia alone
vs no intervention
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Regional analgesia +
tocolysis vs tocolysis
2 171 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.03, 1.04]
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Comparison 15. Systemic opioids (E) vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Failure to achieve cephalic
vaginal birth (composite
outcome: caesarean section +
vaginal breech birth)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Fetal bradycardia (primary) 1 60 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.09, 1.04]
4 Caesarean section (primary) 1 60 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.63, 1.57]
5 Failed external cephalic version 1 60 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.47, 1.26]
6 Difficult external cephalic
version
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Maternal palpitations 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Maternal headaches 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Maternal hypotension 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Operative vaginal birth 1 60 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.20, 4.27]
11 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Maternal morbidity 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Perinatal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14 Perinatal morbidity 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15 Pain score (0-10 scale, lowest
best) (non-prespecified)
1 60 Mean Difference (IV, Fixed, 95% CI) -1.8 [-3.04, -0.56]
16 Maternal satisfaction
score (lower score worst)
(non-prespecified)
1 60 Mean Difference (IV, Fixed, 95% CI) 2.60 [1.25, 3.95]
17 Nausea and vomiting
(non-prespecified)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.03, 2.83]
18 Dizziness (non-prespecified) 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.38]
19 Drowsiness (non-prespecified) 1 60 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [0.12, 66.40]
Comparison 18. Systemic opioids (E) vs regional anaesthesia (C)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Failure to achieve cephalic
vaginal birth (composite
outcome: caesarean section +
vaginal breech birth)
1 95 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.90, 1.54]
3 Caesarean section (primary) 1 95 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.90, 1.54]
4 Fetal bradycardia (primary) 1 94 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.24, 2.09]
5 Failed external cephalic version 1 95 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.93, 1.80]
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6 Difficult external cephalic
version
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Maternal palpitations 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Maternal headaches 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Maternal hypotension 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Operative vaginal birth 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Maternal morbidity 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Perinatal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14 Perinatal morbidity 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 21. Tocolytics vs placebo - nullips vs multips
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
2 249 Risk Ratio (M-H, Random, 95% CI) 1.89 [0.98, 3.62]
1.1 Nullips 2 170 Risk Ratio (M-H, Random, 95% CI) 2.13 [1.02, 4.45]
1.2 Multips 2 79 Risk Ratio (M-H, Random, 95% CI) 2.02 [0.45, 9.15]
2 Caesarean section (primary) 2 249 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.74, 0.95]
2.1 Nullips 2 170 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.75, 0.97]
2.2 Multips 2 79 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.38, 1.17]
3 Fetal bradycardia (primary) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Nullips 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Multips 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Failed external cephalic version 6 513 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.66, 0.92]
4.1 Nullips 6 323 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.76, 0.95]
4.2 Multips 6 190 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.38, 0.95]
Comparison 22. Tocolytic (nifedipine) vs tocolytic (terbutaline) - nullips vs multips
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Nullips 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Multips 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Caesarean section (primary) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Nullips 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Multips 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Fetal bradycardia (primary) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Nullips 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Multips 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Failed ECV 1 86 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.90, 2.13]
4.1 Nullips 1 39 Risk Ratio (M-H, Random, 95% CI) 1.60 [0.83, 3.10]
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4.2 Multips 1 47 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.69, 2.19]
4.3 Caesarean section
(primary)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 23. Hypnosis vs neurolinguistic programming
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Failure to achieve cephalic
vaginal birth (composite
outcome: caesarean section +
vaginal breech birth)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Caesarean section (primary) 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Fetal bradycardia (primary) 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5 Failed external cephalic version 1 80 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.74, 1.57]
6 Difficult external cephalic
version
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7 Maternal palpitations 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8 Maternal headaches 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9 Maternal hypotension 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10 Operative vaginal birth 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11 Maternal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12 Maternal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13 Perinatal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14 Perinatal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15 Good pain relief (higher scores
better) (non-prespecified)
1 80 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.87, 0.67]
Comparison 24. Talcum powder vs gel
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cephalic presentation at birth
(primary)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Failure to achieve cephalic
vaginal birth (composite
outcome: caesarean section +
vaginal breech birth)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Caesarean section (primary) 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Fetal bradycardia (primary) 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5 Failed external cephalic version
(after first round of attempts)
1 95 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.84, 1.89]
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6 Difficult external cephalic
version
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7 Maternal palpitations 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8 Maternal headaches 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9 Maternal hypotension 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10 Operative vaginal birth 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11 Maternal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12 Maternal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13 Perinatal mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14 Perinatal morbidity 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 1 Cephalic presentation at birth
(primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 1 Cephalic presentation at birth (primary)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Fernandez 1997 24/52 13/51 19.9 % 1.81 [ 1.04, 3.15 ]
Impey 2005 19/62 7/62 14.0 % 2.71 [ 1.23, 5.99 ]
Nor Azlin 2005 14/30 7/30 14.8 % 2.00 [ 0.94, 4.25 ]
Robertson 1987 20/30 19/28 26.0 % 0.98 [ 0.69, 1.41 ]
Vani 2009 40/57 21/57 25.3 % 1.90 [ 1.30, 2.78 ]
Subtotal (95% CI) 231 228 100.0 % 1.68 [ 1.14, 2.48 ]
Total events: 117 (Tocolytics (A)), 67 (Placebo)
Heterogeneity: Tau2 = 0.12; Chi2 = 11.00, df = 4 (P = 0.03); I2 =64%
Test for overall effect: Z = 2.62 (P = 0.0088)
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Kok 2008 67/154 60/156 100.0 % 1.13 [ 0.87, 1.48 ]
Subtotal (95% CI) 154 156 100.0 % 1.13 [ 0.87, 1.48 ]
Total events: 67 (Tocolytics (A)), 60 (Placebo)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours placebo Favours tocolytic
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(. . . Continued)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.90 (P = 0.37)
4 Nitric oxide donors - parenteral
Hilton 2009 24/65 14/60 100.0 % 1.58 [ 0.91, 2.76 ]
Subtotal (95% CI) 65 60 100.0 % 1.58 [ 0.91, 2.76 ]
Total events: 24 (Tocolytics (A)), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
5 Nitric oxide donors - oral or sublingual
Bujold 2003a 24/50 32/49 100.0 % 0.74 [ 0.52, 1.05 ]
Subtotal (95% CI) 50 49 100.0 % 0.74 [ 0.52, 1.05 ]
Total events: 24 (Tocolytics (A)), 32 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.088)
Test for subgroup differences: Chi2 = 11.09, df = 3 (P = 0.01), I2 =73%
0.01 0.1 1 10 100
Favours placebo Favours tocolytic
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Analysis 1.2. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 2 Failure to achieve cephalic vaginal
birth (composite outcome: caesarean section + vaginal breech birth).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 2 Failure to achieve cephalic vaginal birth (composite outcome: caesarean section + vaginal breech birth)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Fernandez 1997 31/52 40/51 30.5 % 0.76 [ 0.58, 0.99 ]
Impey 2005 46/62 58/62 43.3 % 0.79 [ 0.68, 0.93 ]
Robertson 1987 12/30 10/28 8.9 % 1.12 [ 0.58, 2.17 ]
Vani 2009 18/57 36/57 17.3 % 0.50 [ 0.33, 0.77 ]
Subtotal (95% CI) 201 198 100.0 % 0.75 [ 0.60, 0.92 ]
Total events: 107 (Tocolytics (A)), 144 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.57, df = 3 (P = 0.13); I2 =46%
Test for overall effect: Z = 2.69 (P = 0.0072)
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Bujold 2003a 31/50 25/49 100.0 % 1.22 [ 0.86, 1.72 ]
Subtotal (95% CI) 50 49 100.0 % 1.22 [ 0.86, 1.72 ]
Total events: 31 (Tocolytics (A)), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Chi2 = 5.45, df = 1 (P = 0.02), I2 =82%
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Analysis 1.3. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 3 Caesarean section (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 3 Caesarean section (primary)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Fernandez 1997 30/52 39/51 18.7 % 0.75 [ 0.57, 1.00 ]
Impey 2005 41/62 53/62 28.0 % 0.77 [ 0.63, 0.95 ]
Marquette 1996 76/138 94/145 30.2 % 0.85 [ 0.70, 1.03 ]
Nor Azlin 2005 17/30 23/30 12.0 % 0.74 [ 0.51, 1.07 ]
Robertson 1987 8/30 5/28 2.0 % 1.49 [ 0.55, 4.03 ]
Vani 2009 18/57 36/57 9.3 % 0.50 [ 0.33, 0.77 ]
Subtotal (95% CI) 369 373 100.0 % 0.77 [ 0.67, 0.88 ]
Total events: 190 (Tocolytics (A)), 250 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.65, df = 5 (P = 0.25); I2 =25%
Test for overall effect: Z = 3.71 (P = 0.00021)
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Kok 2008 79/154 72/156 100.0 % 1.11 [ 0.88, 1.40 ]
Subtotal (95% CI) 154 156 100.0 % 1.11 [ 0.88, 1.40 ]
Total events: 79 (Tocolytics (A)), 72 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
4 Nitric oxide donors - parenteral
Hilton 2009 44/65 49/60 100.0 % 0.83 [ 0.67, 1.02 ]
Subtotal (95% CI) 65 60 100.0 % 0.83 [ 0.67, 1.02 ]
Total events: 44 (Tocolytics (A)), 49 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 7.39, df = 2 (P = 0.02), I2 =73%
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Analysis 1.4. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 4 Fetal bradycardia (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 4 Fetal bradycardia (primary)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Robertson 1987 1/30 0/28 100.0 % 2.81 [ 0.12, 66.17 ]
Subtotal (95% CI) 30 28 100.0 % 2.81 [ 0.12, 66.17 ]
Total events: 1 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Kok 2008 12/154 11/156 100.0 % 1.11 [ 0.50, 2.43 ]
Subtotal (95% CI) 154 156 100.0 % 1.11 [ 0.50, 2.43 ]
Total events: 12 (Tocolytics (A)), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Bujold 2003a 2/50 5/49 100.0 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 50 49 100.0 % 0.39 [ 0.08, 1.93 ]
Total events: 2 (Tocolytics (A)), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 1.78, df = 2 (P = 0.41), I2 =0.0%
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Analysis 1.5. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 5 Failed external cephalic version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 5 Failed external cephalic version
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Chung 1996 8/25 18/25 5.3 % 0.44 [ 0.24, 0.83 ]
Fernandez 1997 25/52 37/51 13.8 % 0.66 [ 0.48, 0.92 ]
Impey 2005 45/62 57/62 25.4 % 0.79 [ 0.67, 0.94 ]
Marquette 1996 66/138 84/145 20.8 % 0.83 [ 0.66, 1.03 ]
Nor Azlin 2005 15/30 23/30 10.3 % 0.65 [ 0.43, 0.98 ]
Robertson 1987 10/30 9/28 3.9 % 1.04 [ 0.50, 2.17 ]
Stock 1993 12/42 12/21 5.6 % 0.50 [ 0.27, 0.92 ]
Tan 1989 15/30 8/15 5.7 % 0.94 [ 0.52, 1.70 ]
Vani 2009 17/57 36/57 9.1 % 0.47 [ 0.30, 0.74 ]
Subtotal (95% CI) 466 434 100.0 % 0.70 [ 0.60, 0.82 ]
Total events: 213 (Tocolytics (A)), 284 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 12.19, df = 8 (P = 0.14); I2 =34%
Test for overall effect: Z = 4.47 (P < 0.00001)
2 Beta stimulants - oral or sublingual
Tan 1989 16/30 8/15 100.0 % 1.00 [ 0.56, 1.79 ]
Subtotal (95% CI) 30 15 100.0 % 1.00 [ 0.56, 1.79 ]
Total events: 16 (Tocolytics (A)), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Calcium channel blockers - oral or sublingual
Kok 2008 90/154 98/156 100.0 % 0.93 [ 0.78, 1.11 ]
Subtotal (95% CI) 154 156 100.0 % 0.93 [ 0.78, 1.11 ]
Total events: 90 (Tocolytics (A)), 98 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
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(. . . Continued)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
4 Nitric oxide donors - parenteral
Hilton 2009 45/65 49/61 100.0 % 0.86 [ 0.70, 1.06 ]
Subtotal (95% CI) 65 61 100.0 % 0.86 [ 0.70, 1.06 ]
Total events: 45 (Tocolytics (A)), 49 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
5 Nitric oxide donors - oral or sublingual
Bujold 2003a 26/50 18/49 45.8 % 1.42 [ 0.90, 2.23 ]
Yanny 2000 22/31 23/26 54.2 % 0.80 [ 0.62, 1.05 ]
Subtotal (95% CI) 81 75 100.0 % 1.04 [ 0.55, 1.96 ]
Total events: 48 (Tocolytics (A)), 41 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 5.83, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 6.95, df = 4 (P = 0.14), I2 =42%
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Analysis 1.6. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 6 Difficult external cephalic version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 6 Difficult external cephalic version
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Stock 1993 5/42 5/21 100.0 % 0.50 [ 0.16, 1.54 ]
Subtotal (95% CI) 42 21 100.0 % 0.50 [ 0.16, 1.54 ]
Total events: 5 (Tocolytics (A)), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 7 Maternal palpitations.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 7 Maternal palpitations
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Vani 2009 2/57 0/57 100.0 % 5.00 [ 0.25, 101.89 ]
Subtotal (95% CI) 57 57 100.0 % 5.00 [ 0.25, 101.89 ]
Total events: 2 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.30)
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Hilton 2009 1/59 2/58 100.0 % 0.49 [ 0.05, 5.27 ]
Subtotal (95% CI) 59 58 100.0 % 0.49 [ 0.05, 5.27 ]
Total events: 1 (Tocolytics (A)), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
5 Nitric oxide donors - oral or sublingual
Bujold 2003a 0/50 0/49 Not estimable
Subtotal (95% CI) 50 49 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =29%
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Analysis 1.8. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 8 Maternal headaches.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 8 Maternal headaches
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Hilton 2009 9/59 0/58 100.0 % 18.68 [ 1.11, 313.77 ]
Subtotal (95% CI) 59 58 100.0 % 18.68 [ 1.11, 313.77 ]
Total events: 9 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
5 Nitric oxide donors - oral or sublingual
Bujold 2003a 21/50 2/49 100.0 % 10.29 [ 2.55, 41.56 ]
Subtotal (95% CI) 50 49 100.0 % 10.29 [ 2.55, 41.56 ]
Total events: 21 (Tocolytics (A)), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 1.9. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 9 Maternal hypotension.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 9 Maternal hypotension
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Hilton 2009 3/59 2/58 100.0 % 1.47 [ 0.26, 8.50 ]
Subtotal (95% CI) 59 58 100.0 % 1.47 [ 0.26, 8.50 ]
Total events: 3 (Tocolytics (A)), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
5 Nitric oxide donors - oral or sublingual
Bujold 2003a 6/50 1/49 100.0 % 5.88 [ 0.73, 47.07 ]
Subtotal (95% CI) 50 49 100.0 % 5.88 [ 0.73, 47.07 ]
Total events: 6 (Tocolytics (A)), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
Test for subgroup differences: Chi2 = 0.99, df = 1 (P = 0.32), I2 =0.0%
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Analysis 1.10. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 10 Operative vaginal birth.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 10 Operative vaginal birth
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Kok 2008 3/154 9/156 100.0 % 0.34 [ 0.09, 1.22 ]
Subtotal (95% CI) 154 156 100.0 % 0.34 [ 0.09, 1.22 ]
Total events: 3 (Tocolytics (A)), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.098)
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 13 Perinatal mortality.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 13 Perinatal mortality
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Kok 2008 0/154 0/156 Not estimable
Subtotal (95% CI) 154 156 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 1.15. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 15 Vaginal breech birth.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 15 Vaginal breech birth
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Impey 2005 5/62 5/62 100.0 % 1.00 [ 0.30, 3.28 ]
Subtotal (95% CI) 62 62 100.0 % 1.00 [ 0.30, 3.28 ]
Total events: 5 (Tocolytics (A)), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 16 Apgar < 7 at 5 minutes (not
prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 16 Apgar < 7 at 5 minutes (not prespecified)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Fernandez 1997 0/52 0/51 Not estimable
Impey 2005 0/62 0/62 Not estimable
Subtotal (95% CI) 114 113 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
97Interventions for helping to turn term breech babies to head first presentation when using external cephalic version (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.17. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 17 Neonatal seizures (not
prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 17 Neonatal seizures (not prespecified)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Impey 2005 0/62 0/62 Not estimable
Subtotal (95% CI) 62 62 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 1.18. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 18 Admission to neonatal unit (not
prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 18 Admission to neonatal unit (not prespecified)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Impey 2005 2/62 2/62 39.5 % 1.00 [ 0.15, 6.88 ]
Vani 2009 3/57 3/57 60.5 % 1.00 [ 0.21, 4.75 ]
Subtotal (95% CI) 119 119 100.0 % 1.00 [ 0.30, 3.36 ]
Total events: 5 (Tocolytics (A)), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 19 Birth trauma (not prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 19 Birth trauma (not prespecified)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Vani 2009 0/57 0/57 Not estimable
Subtotal (95% CI) 57 57 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 1.20. Comparison 1 Tocolytic drugs (A) vs placebo, Outcome 20 Maternal flushing (not
prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 1 Tocolytic drugs (A) vs placebo
Outcome: 20 Maternal flushing (not prespecified)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta stimulants - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Beta stimulants - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcium channel blockers - oral or sublingual
Kok 2008 11/154 0/156 100.0 % 23.30 [ 1.38, 391.91 ]
Subtotal (95% CI) 154 156 100.0 % 23.30 [ 1.38, 391.91 ]
Total events: 11 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
4 Nitric oxide donors - parenteral
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Nitric oxide donors - oral or sublingual
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytics (A)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 1 Cephalic presentation
at birth (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 1 Cephalic presentation at birth (primary)
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Collaris 2009 16/44 27/46 100.0 % 0.62 [ 0.39, 0.98 ]
Subtotal (95% CI) 44 46 100.0 % 0.62 [ 0.39, 0.98 ]
Total events: 16 (Intervention tocolytic), 27 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Bujold 2003b 9/36 17/38 100.0 % 0.56 [ 0.29, 1.09 ]
Subtotal (95% CI) 36 38 100.0 % 0.56 [ 0.29, 1.09 ]
Total events: 9 (Intervention tocolytic), 17 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.2. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 2 Failure to achieve
cephalic vaginal birth (composite outcome: caesarean section + vaginal breech birth).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 2 Failure to achieve cephalic vaginal birth (composite outcome: caesarean section + vaginal breech birth)
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Bujold 2003b 29/36 27/38 100.0 % 1.13 [ 0.88, 1.47 ]
Subtotal (95% CI) 36 38 100.0 % 1.13 [ 0.88, 1.47 ]
Total events: 29 (Intervention tocolytic), 27 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 3 Caesarean section
(primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 3 Caesarean section (primary)
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Collaris 2009 34/44 26/46 51.1 % 1.37 [ 1.01, 1.85 ]
Nor Azlin 2008 32/43 23/37 48.9 % 1.20 [ 0.88, 1.63 ]
Subtotal (95% CI) 87 83 100.0 % 1.28 [ 1.03, 1.59 ]
Total events: 66 (Intervention tocolytic), 49 (Comparison tocolytic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.4. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 4 Fetal bradycardia
(primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 4 Fetal bradycardia (primary)
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Collaris 2009 6/43 6/41 81.8 % 0.95 [ 0.33, 2.72 ]
Nor Azlin 2008 3/43 1/43 18.2 % 3.00 [ 0.32, 27.71 ]
Subtotal (95% CI) 86 84 100.0 % 1.17 [ 0.46, 3.03 ]
Total events: 9 (Intervention tocolytic), 7 (Comparison tocolytic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Bujold 2003b 2/36 2/38 100.0 % 1.06 [ 0.16, 7.10 ]
Subtotal (95% CI) 36 38 100.0 % 1.06 [ 0.16, 7.10 ]
Total events: 2 (Intervention tocolytic), 2 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.5. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 5 Failed external cephalic
version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 5 Failed external cephalic version
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Collaris 2009 29/44 22/46 57.3 % 1.38 [ 0.95, 1.99 ]
Nor Azlin 2008 26/43 18/43 42.7 % 1.44 [ 0.94, 2.21 ]
Subtotal (95% CI) 87 89 100.0 % 1.41 [ 1.06, 1.86 ]
Total events: 55 (Intervention tocolytic), 40 (Comparison tocolytic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Bujold 2003b 27/36 21/38 63.2 % 1.36 [ 0.96, 1.91 ]
El-Sayed 2004 23/30 13/29 36.8 % 1.71 [ 1.09, 2.68 ]
Subtotal (95% CI) 66 67 100.0 % 1.48 [ 1.13, 1.94 ]
Total events: 50 (Intervention tocolytic), 34 (Comparison tocolytic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.6. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 6 Difficult external
cephalic version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 6 Difficult external cephalic version
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Collaris 2009 2/44 0/46 100.0 % 5.22 [ 0.26, 105.81 ]
Subtotal (95% CI) 44 46 100.0 % 5.22 [ 0.26, 105.81 ]
Total events: 2 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours interv tocolytic Favours comp tocolytic
107Interventions for helping to turn term breech babies to head first presentation when using external cephalic version (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.7. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 7 Maternal palpitations.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 7 Maternal palpitations
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Nor Azlin 2008 4/43 5/43 100.0 % 0.80 [ 0.23, 2.78 ]
Subtotal (95% CI) 43 43 100.0 % 0.80 [ 0.23, 2.78 ]
Total events: 4 (Intervention tocolytic), 5 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Bujold 2003b 2/36 4/38 100.0 % 0.53 [ 0.10, 2.71 ]
Subtotal (95% CI) 36 38 100.0 % 0.53 [ 0.10, 2.71 ]
Total events: 2 (Intervention tocolytic), 4 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.8. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 8 Maternal headaches.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 8 Maternal headaches
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Bujold 2003b 10/36 3/38 100.0 % 3.52 [ 1.05, 11.76 ]
Subtotal (95% CI) 36 38 100.0 % 3.52 [ 1.05, 11.76 ]
Total events: 10 (Intervention tocolytic), 3 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.9. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 9 Maternal hypotension.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 9 Maternal hypotension
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Bujold 2003b 3/36 1/38 100.0 % 3.17 [ 0.35, 29.06 ]
Subtotal (95% CI) 36 38 100.0 % 3.17 [ 0.35, 29.06 ]
Total events: 3 (Intervention tocolytic), 1 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.16. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 16 Apgar < 7 at 5
minutes (not prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 16 Apgar < 7 at 5 minutes (not prespecified)
Study or subgroup Tocolytic 1 Tocolytic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Collaris 2009 0/44 0/45 Not estimable
Subtotal (95% CI) 44 45 Not estimable
Total events: 0 (Tocolytic 1), 0 (Tocolytic 2)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytic 1), 0 (Tocolytic 2)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Tocolytic 1), 0 (Tocolytic 2)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.18. Comparison 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A), Outcome 18 Admissions to
neonatal unit (not prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 2 Tocolytic drug 1 (A) vs tocolytic drug 2 (A)
Outcome: 18 Admissions to neonatal unit (not prespecified)
Study or subgroup Intervention tocolytic
Comparison
tocolytic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcium channel blockers (A2) vs beta stimulants (A1)
Nor Azlin 2008 0/43 0/43 Not estimable
Subtotal (95% CI) 43 43 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Nitric oxide donors (A3) vs beta stimulants (A1)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Nitric oxide donors (A3) vs calcium channel blockers (A2)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 43 43 Not estimable
Total events: 0 (Intervention tocolytic), 0 (Comparison tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 3.5. Comparison 3 Vibroacoustic stimulation (B) vs placebo, Outcome 5 Failed external cephalic
version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 3 Vibroacoustic stimulation (B) vs placebo
Outcome: 5 Failed external cephalic version
Study or subgroup Vibroacoustics (B) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Johnson 1995 1/12 10/11 100.0 % 0.09 [ 0.01, 0.60 ]
Total (95% CI) 12 11 100.0 % 0.09 [ 0.01, 0.60 ]
Total events: 1 (Vibroacoustics (B)), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Regional analgesia (with or without tocolysis) vs no intervention of regional
analgesia (with or without tocolysis), Outcome 1 Cephalic presentation at birth (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 6 Regional analgesia (with or without tocolysis) vs no intervention of regional analgesia (with or without tocolysis)
Outcome: 1 Cephalic presentation at birth (primary)
Study or subgroup
Regional
analgesia
(C) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Regional analgesia alone vs no intervention
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Regional analgesia (C)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Regional analgesia + tocolysis vs tocolysis
Dugoff 1999 20/50 26/52 34.5 % 0.80 [ 0.52, 1.24 ]
Mancuso 2000 32/54 19/54 34.8 % 1.68 [ 1.10, 2.57 ]
Schorr 1997 24/35 10/34 30.8 % 2.33 [ 1.32, 4.11 ]
Subtotal (95% CI) 139 140 100.0 % 1.44 [ 0.78, 2.66 ]
Total events: 76 (Regional analgesia (C)), 55 (Placebo)
Heterogeneity: Tau2 = 0.24; Chi2 = 10.19, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 1.16 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Regional analgesia (with or without tocolysis) vs no intervention of regional
analgesia (with or without tocolysis), Outcome 3 Caesarean section (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 6 Regional analgesia (with or without tocolysis) vs no intervention of regional analgesia (with or without tocolysis)
Outcome: 3 Caesarean section (primary)
Study or subgroup
Regional
analgesia
(C) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Regional analgesia alone vs no intervention
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Regional analgesia (C)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Regional analgesia + tocolysis vs tocolysis
Dugoff 1999 34/50 27/52 34.7 % 1.31 [ 0.95, 1.81 ]
Mancuso 2000 25/54 37/54 34.4 % 0.68 [ 0.48, 0.95 ]
Schorr 1997 12/35 27/34 30.9 % 0.43 [ 0.26, 0.70 ]
Subtotal (95% CI) 139 140 100.0 % 0.74 [ 0.40, 1.37 ]
Total events: 71 (Regional analgesia (C)), 91 (Placebo)
Heterogeneity: Tau2 = 0.26; Chi2 = 16.08, df = 2 (P = 0.00032); I2 =88%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Regional analgesia (with or without tocolysis) vs no intervention of regional
analgesia (with or without tocolysis), Outcome 4 Fetal bradycardia (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 6 Regional analgesia (with or without tocolysis) vs no intervention of regional analgesia (with or without tocolysis)
Outcome: 4 Fetal bradycardia (primary)
Study or subgroup
Regional
analgesia
(C) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Regional analgesia alone vs no intervention
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Regional analgesia (C)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Regional analgesia + tocolysis vs tocolysis
Dugoff 1999 11/50 6/52 76.1 % 1.91 [ 0.76, 4.76 ]
Mancuso 2000 2/54 3/54 23.9 % 0.67 [ 0.12, 3.83 ]
Subtotal (95% CI) 104 106 100.0 % 1.48 [ 0.62, 3.57 ]
Total events: 13 (Regional analgesia (C)), 9 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Regional analgesia (with or without tocolysis) vs no intervention of regional
analgesia (with or without tocolysis), Outcome 5 Failed external cephalic version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 6 Regional analgesia (with or without tocolysis) vs no intervention of regional analgesia (with or without tocolysis)
Outcome: 5 Failed external cephalic version
Study or subgroup
Regional
analgesia
(C) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Regional analgesia alone vs no intervention
Delisle 2001 44/73 46/68 100.0 % 0.89 [ 0.70, 1.14 ]
Subtotal (95% CI) 73 68 100.0 % 0.89 [ 0.70, 1.14 ]
Total events: 44 (Regional analgesia (C)), 46 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 Regional analgesia + tocolysis vs tocolysis
Dugoff 1999 28/50 30/52 27.8 % 0.97 [ 0.69, 1.36 ]
Mancuso 2000 22/54 36/54 26.3 % 0.61 [ 0.42, 0.89 ]
Schorr 1997 9/35 18/34 16.2 % 0.49 [ 0.25, 0.93 ]
Weiniger 2007 12/36 23/34 20.5 % 0.49 [ 0.29, 0.83 ]
Weiniger 2010 4/27 14/33 9.2 % 0.35 [ 0.13, 0.94 ]
Subtotal (95% CI) 202 207 100.0 % 0.61 [ 0.43, 0.86 ]
Total events: 75 (Regional analgesia (C)), 121 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 9.16, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Chi2 = 3.10, df = 1 (P = 0.08), I2 =68%
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Analysis 6.9. Comparison 6 Regional analgesia (with or without tocolysis) vs no intervention of regional
analgesia (with or without tocolysis), Outcome 9 Maternal hypotension.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 6 Regional analgesia (with or without tocolysis) vs no intervention of regional analgesia (with or without tocolysis)
Outcome: 9 Maternal hypotension
Study or subgroup
Regional
analgesia
(C) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Regional analgesia alone vs no intervention
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Regional analgesia (C)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Regional analgesia + tocolysis vs tocolysis
Dugoff 1999 4/50 0/52 48.8 % 9.35 [ 0.52, 169.36 ]
Mancuso 2000 0/54 0/54 Not estimable
Weiniger 2007 7/36 0/34 51.2 % 14.19 [ 0.84, 239.28 ]
Subtotal (95% CI) 140 140 100.0 % 11.58 [ 1.53, 87.50 ]
Total events: 11 (Regional analgesia (C)), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 6.15. Comparison 6 Regional analgesia (with or without tocolysis) vs no intervention of regional
analgesia (with or without tocolysis), Outcome 15 Placental abruption (not prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 6 Regional analgesia (with or without tocolysis) vs no intervention of regional analgesia (with or without tocolysis)
Outcome: 15 Placental abruption (not prespecified)
Study or subgroup
Regional
analgesia
(C) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Regional analgesia alone vs no intervention
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Regional analgesia (C)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Regional analgesia + tocolysis vs tocolysis
Dugoff 1999 0/50 1/52 100.0 % 0.35 [ 0.01, 8.31 ]
Subtotal (95% CI) 50 52 100.0 % 0.35 [ 0.01, 8.31 ]
Total events: 0 (Regional analgesia (C)), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 6.16. Comparison 6 Regional analgesia (with or without tocolysis) vs no intervention of regional
analgesia (with or without tocolysis), Outcome 16 Maternal discomfort (not prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 6 Regional analgesia (with or without tocolysis) vs no intervention of regional analgesia (with or without tocolysis)
Outcome: 16 Maternal discomfort (not prespecified)
Study or subgroup
Regional
analgesia
(C) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Regional analgesia alone vs no intervention
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Regional analgesia (C)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Regional analgesia + tocolysis vs tocolysis
Dugoff 1999 0/50 4/52 35.3 % 0.12 [ 0.01, 2.09 ]
Schorr 1997 1/35 4/34 64.7 % 0.24 [ 0.03, 2.06 ]
Subtotal (95% CI) 85 86 100.0 % 0.19 [ 0.03, 1.04 ]
Total events: 1 (Regional analgesia (C)), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
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Analysis 15.3. Comparison 15 Systemic opioids (E) vs placebo, Outcome 3 Fetal bradycardia (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 3 Fetal bradycardia (primary)
Study or subgroup Systemic opioids (E) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Munoz 2014 3/31 9/29 100.0 % 0.31 [ 0.09, 1.04 ]
Total (95% CI) 31 29 100.0 % 0.31 [ 0.09, 1.04 ]
Total events: 3 (Systemic opioids (E)), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
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Analysis 15.4. Comparison 15 Systemic opioids (E) vs placebo, Outcome 4 Caesarean section (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 4 Caesarean section (primary)
Study or subgroup Systemic opioids (E) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Munoz 2014 17/31 16/29 100.0 % 0.99 [ 0.63, 1.57 ]
Total (95% CI) 31 29 100.0 % 0.99 [ 0.63, 1.57 ]
Total events: 17 (Systemic opioids (E)), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 15.5. Comparison 15 Systemic opioids (E) vs placebo, Outcome 5 Failed external cephalic version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 5 Failed external cephalic version
Study or subgroup Systemic opioids (E) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Munoz 2014 14/31 17/29 100.0 % 0.77 [ 0.47, 1.26 ]
Total (95% CI) 31 29 100.0 % 0.77 [ 0.47, 1.26 ]
Total events: 14 (Systemic opioids (E)), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 15.10. Comparison 15 Systemic opioids (E) vs placebo, Outcome 10 Operative vaginal birth.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 10 Operative vaginal birth
Study or subgroup Systemic opioids (E) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Munoz 2014 3/31 3/29 100.0 % 0.94 [ 0.20, 4.27 ]
Total (95% CI) 31 29 100.0 % 0.94 [ 0.20, 4.27 ]
Total events: 3 (Systemic opioids (E)), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 15.15. Comparison 15 Systemic opioids (E) vs placebo, Outcome 15 Pain score (0-10 scale, lowest
best) (non-prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 15 Pain score (0-10 scale, lowest best) (non-prespecified)
Study or subgroup Systemic opioids (E) Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Munoz 2014 31 4.7 (2.5) 29 6.5 (2.4) 100.0 % -1.80 [ -3.04, -0.56 ]
Total (95% CI) 31 29 100.0 % -1.80 [ -3.04, -0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.85 (P = 0.0044)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours opioid Favours placebo
Analysis 15.16. Comparison 15 Systemic opioids (E) vs placebo, Outcome 16 Maternal satisfaction score
(lower score worst) (non-prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 16 Maternal satisfaction score (lower score worst) (non-prespecified)
Study or subgroup Systemic opioids (E) Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Munoz 2014 31 9.5 (1.3) 29 6.9 (3.5) 100.0 % 2.60 [ 1.25, 3.95 ]
Total (95% CI) 31 29 100.0 % 2.60 [ 1.25, 3.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours systemic opioid
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Analysis 15.17. Comparison 15 Systemic opioids (E) vs placebo, Outcome 17 Nausea and vomiting (non-
prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 17 Nausea and vomiting (non-prespecified)
Study or subgroup Systemic opioids (E) Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Munoz 2014 1/31 3/29 100.0 % 0.31 [ 0.03, 2.83 ]
Total (95% CI) 31 29 100.0 % 0.31 [ 0.03, 2.83 ]
Total events: 1 (Systemic opioids (E)), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours systemic opioid Favours placebo
Analysis 15.18. Comparison 15 Systemic opioids (E) vs placebo, Outcome 18 Dizziness (non-prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 18 Dizziness (non-prespecified)
Study or subgroup Systemic opioids (E) Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Munoz 2014 0/31 1/29 100.0 % 0.31 [ 0.01, 7.38 ]
Total (95% CI) 31 29 100.0 % 0.31 [ 0.01, 7.38 ]
Total events: 0 (Systemic opioids (E)), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours systemic opioid Favours placebo
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Analysis 15.19. Comparison 15 Systemic opioids (E) vs placebo, Outcome 19 Drowsiness (non-prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 15 Systemic opioids (E) vs placebo
Outcome: 19 Drowsiness (non-prespecified)
Study or subgroup Systemic opioids (E) Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Munoz 2014 1/31 0/29 100.0 % 2.81 [ 0.12, 66.40 ]
Total (95% CI) 31 29 100.0 % 2.81 [ 0.12, 66.40 ]
Total events: 1 (Systemic opioids (E)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours systemic opioid Favours placebo
Analysis 18.2. Comparison 18 Systemic opioids (E) vs regional anaesthesia (C), Outcome 2 Failure to
achieve cephalic vaginal birth (composite outcome: caesarean section + vaginal breech birth).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 18 Systemic opioids (E) vs regional anaesthesia (C)
Outcome: 2 Failure to achieve cephalic vaginal birth (composite outcome: caesarean section + vaginal breech birth)
Study or subgroup Systemic opioids (E)
Regional
anaesthesia
(C) Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sullivan 2009 36/48 30/47 100.0 % 1.18 [ 0.90, 1.54 ]
Total (95% CI) 48 47 100.0 % 1.18 [ 0.90, 1.54 ]
Total events: 36 (Systemic opioids (E)), 30 (Regional anaesthesia (C))
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours opiod Favours regional analg
125Interventions for helping to turn term breech babies to head first presentation when using external cephalic version (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 18.3. Comparison 18 Systemic opioids (E) vs regional anaesthesia (C), Outcome 3 Caesarean
section (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 18 Systemic opioids (E) vs regional anaesthesia (C)
Outcome: 3 Caesarean section (primary)
Study or subgroup Systemic opioids (E)
Regional
anaesthesia
(C) Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sullivan 2009 36/48 30/47 100.0 % 1.18 [ 0.90, 1.54 ]
Total (95% CI) 48 47 100.0 % 1.18 [ 0.90, 1.54 ]
Total events: 36 (Systemic opioids (E)), 30 (Regional anaesthesia (C))
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours opioids Favours regional analg
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Analysis 18.4. Comparison 18 Systemic opioids (E) vs regional anaesthesia (C), Outcome 4 Fetal
bradycardia (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 18 Systemic opioids (E) vs regional anaesthesia (C)
Outcome: 4 Fetal bradycardia (primary)
Study or subgroup Systemic opioids (E)
Regional
anaesthesia
(C) Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sullivan 2009 5/47 7/47 100.0 % 0.71 [ 0.24, 2.09 ]
Total (95% CI) 47 47 100.0 % 0.71 [ 0.24, 2.09 ]
Total events: 5 (Systemic opioids (E)), 7 (Regional anaesthesia (C))
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 18.5. Comparison 18 Systemic opioids (E) vs regional anaesthesia (C), Outcome 5 Failed external
cephalic version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 18 Systemic opioids (E) vs regional anaesthesia (C)
Outcome: 5 Failed external cephalic version
Study or subgroup Systemic opioids (E)
Regional
anaesthesia
(C) Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sullivan 2009 33/48 25/47 100.0 % 1.29 [ 0.93, 1.80 ]
Total (95% CI) 48 47 100.0 % 1.29 [ 0.93, 1.80 ]
Total events: 33 (Systemic opioids (E)), 25 (Regional anaesthesia (C))
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 21.1. Comparison 21 Tocolytics vs placebo - nullips vs multips, Outcome 1 Cephalic presentation
at birth (primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 21 Tocolytics vs placebo - nullips vs multips
Outcome: 1 Cephalic presentation at birth (primary)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Nullips
Hilton 2009 12/42 4/39 22.9 % 2.79 [ 0.98, 7.92 ]
Impey 2005 8/44 5/45 23.1 % 1.64 [ 0.58, 4.62 ]
Subtotal (95% CI) 86 84 46.0 % 2.13 [ 1.02, 4.45 ]
Total events: 20 (Tocolytics (A)), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.044)
2 Multips
Hilton 2009 12/23 10/21 37.8 % 1.10 [ 0.60, 1.99 ]
Impey 2005 10/18 2/17 16.2 % 4.72 [ 1.20, 18.51 ]
Subtotal (95% CI) 41 38 54.0 % 2.02 [ 0.45, 9.15 ]
Total events: 22 (Tocolytics (A)), 12 (Placebo)
Heterogeneity: Tau2 = 0.93; Chi2 = 4.22, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI) 127 122 100.0 % 1.89 [ 0.98, 3.62 ]
Total events: 42 (Tocolytics (A)), 21 (Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 5.55, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.01 0.1 1 10 100
Favours placebo Favours tocolytics
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Analysis 21.2. Comparison 21 Tocolytics vs placebo - nullips vs multips, Outcome 2 Caesarean section
(primary).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 21 Tocolytics vs placebo - nullips vs multips
Outcome: 2 Caesarean section (primary)
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Nullips
Hilton 2009 32/42 36/39 41.6 % 0.83 [ 0.68, 1.00 ]
Impey 2005 35/44 41/45 49.5 % 0.87 [ 0.73, 1.04 ]
Subtotal (95% CI) 86 84 91.1 % 0.85 [ 0.75, 0.97 ]
Total events: 67 (Tocolytics (A)), 77 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
2 Multips
Hilton 2009 12/23 13/21 5.9 % 0.84 [ 0.50, 1.41 ]
Impey 2005 6/18 12/17 3.0 % 0.47 [ 0.23, 0.97 ]
Subtotal (95% CI) 41 38 8.9 % 0.67 [ 0.38, 1.17 ]
Total events: 18 (Tocolytics (A)), 25 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.67, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 127 122 100.0 % 0.84 [ 0.74, 0.95 ]
Total events: 85 (Tocolytics (A)), 102 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.03, df = 3 (P = 0.39); I2 =1%
Test for overall effect: Z = 2.81 (P = 0.0049)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 21.4. Comparison 21 Tocolytics vs placebo - nullips vs multips, Outcome 4 Failed external cephalic
version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 21 Tocolytics vs placebo - nullips vs multips
Outcome: 4 Failed external cephalic version
Study or subgroup Tocolytics (A) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Nullips
Chung 1996 4/15 10/15 3.0 % 0.40 [ 0.16, 1.00 ]
Hilton 2009 32/42 37/40 20.6 % 0.82 [ 0.68, 1.00 ]
Impey 2005 36/44 41/45 22.0 % 0.90 [ 0.76, 1.06 ]
Nor Azlin 2005 14/22 20/23 12.4 % 0.73 [ 0.51, 1.04 ]
Stock 1993 10/18 6/9 5.7 % 0.83 [ 0.45, 1.55 ]
Tan 1989 24/33 13/17 13.1 % 0.95 [ 0.68, 1.33 ]
Subtotal (95% CI) 174 149 76.6 % 0.85 [ 0.76, 0.95 ]
Total events: 120 (Tocolytics (A)), 127 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.73, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
2 Multips
Chung 1996 4/10 8/10 3.6 % 0.50 [ 0.22, 1.14 ]
Hilton 2009 13/23 12/21 7.6 % 0.99 [ 0.59, 1.66 ]
Impey 2005 9/18 16/17 8.5 % 0.53 [ 0.33, 0.86 ]
Nor Azlin 2005 1/8 3/7 0.7 % 0.29 [ 0.04, 2.21 ]
Stock 1993 2/24 6/12 1.3 % 0.17 [ 0.04, 0.71 ]
Tan 1989 7/27 3/13 1.8 % 1.12 [ 0.35, 3.65 ]
Subtotal (95% CI) 110 80 23.4 % 0.60 [ 0.38, 0.95 ]
Total events: 36 (Tocolytics (A)), 48 (Placebo)
Heterogeneity: Tau2 = 0.12; Chi2 = 8.56, df = 5 (P = 0.13); I2 =42%
Test for overall effect: Z = 2.19 (P = 0.029)
Total (95% CI) 284 229 100.0 % 0.78 [ 0.66, 0.92 ]
Total events: 156 (Tocolytics (A)), 175 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 17.99, df = 11 (P = 0.08); I2 =39%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 2.07, df = 1 (P = 0.15), I2 =52%
0.01 0.1 1 10 100
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Analysis 22.4. Comparison 22 Tocolytic (nifedipine) vs tocolytic (terbutaline) - nullips vs multips, Outcome
4 Failed ECV.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 22 Tocolytic (nifedipine) vs tocolytic (terbutaline) - nullips vs multips
Outcome: 4 Failed ECV
Study or subgroup Nifedipine Terbutaline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Nullips
Nor Azlin 2008 11/18 8/21 43.3 % 1.60 [ 0.83, 3.10 ]
Subtotal (95% CI) 18 21 43.3 % 1.60 [ 0.83, 3.10 ]
Total events: 11 (Nifedipine), 8 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 Multips
Nor Azlin 2008 14/25 10/22 56.7 % 1.23 [ 0.69, 2.19 ]
Subtotal (95% CI) 25 22 56.7 % 1.23 [ 0.69, 2.19 ]
Total events: 14 (Nifedipine), 10 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 Caesarean section (primary)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Nifedipine), 0 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 43 43 100.0 % 1.38 [ 0.90, 2.13 ]
Total events: 25 (Nifedipine), 18 (Terbutaline)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
0.01 0.1 1 10 100
Favours nifedipine Favours terbutaline
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Analysis 23.5. Comparison 23 Hypnosis vs neurolinguistic programming, Outcome 5 Failed external
cephalic version.
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 23 Hypnosis vs neurolinguistic programming
Outcome: 5 Failed external cephalic version
Study or subgroup Hypnosis
Neuro-
linguistic
programm Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Reinhard 2012 25/42 21/38 100.0 % 1.08 [ 0.74, 1.57 ]
Total (95% CI) 42 38 100.0 % 1.08 [ 0.74, 1.57 ]
Total events: 25 (Hypnosis), 21 (Neuro-linguistic programm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypnosis Favours NLP
Analysis 23.15. Comparison 23 Hypnosis vs neurolinguistic programming, Outcome 15 Good pain relief
(higher scores better) (non-prespecified).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 23 Hypnosis vs neurolinguistic programming
Outcome: 15 Good pain relief (higher scores better) (non-prespecified)
Study or subgroup Hypnosis
Neuro-
linguistic
programm
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Reinhard 2012 42 3.3 (1.8) 38 3.4 (1.7) 100.0 % -0.10 [ -0.87, 0.67 ]
Total (95% CI) 42 38 100.0 % -0.10 [ -0.87, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 24.5. Comparison 24 Talcum powder vs gel, Outcome 5 Failed external cephalic version (after first
round of attempts).
Review: Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
Comparison: 24 Talcum powder vs gel
Outcome: 5 Failed external cephalic version (after first round of attempts)
Study or subgroup Talcum powder Gel Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Vallikkannu 2014 27/48 21/47 100.0 % 1.26 [ 0.84, 1.89 ]
Total (95% CI) 48 47 100.0 % 1.26 [ 0.84, 1.89 ]
Total events: 27 (Talcum powder), 21 (Gel)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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WH A T ’ S N E W
Last assessed as up-to-date: 30 September 2014.
Date Event Description
9 March 2016 Amended We have corrected a typographical error in Analysis 6.1 (in relation to Schorr 1997). This edit does not
affect the analysis/results or conclusions of this review
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H I S T O R Y
Protocol first published: Issue 3, 1996
Review first published: Issue 3, 1996
Date Event Description
30 September 2014 New search has been performed We have updated the search and identified 6 new stud-
ies.Wehave included3new trials in the review (Munoz
2014; Reinhard 2012; Vallikkannu 2014), excluded
1 study (Guittier 2013) and identified 2 trial regis-
trations for ongoing studies (Burgos 2012; Passerini
2013)
30 September 2014 New citation required but conclusions have not
changed
Overall results are similar to those reported in the pre-
vious version of the review. A new author joined the
review team to assist with the update. We have incor-
porated a summary of findings table
30 September 2011 New search has been performed Search updated: 10 new trials added to review
We have moved Andarsio 2000 from categorisation as
an ’Included study’ to ’Awaiting classification’ because
we need to know the route of administration of the
drug before we can include data on subgroups in the
updated review. We are trying to obtain this informa-
tion
19 May 2011 New citation required and conclusions have changed Beta stimulants are now recommended for facilitat-
ing external cephalic version at term, but data on ad-
verse effects were insufficient. Data on calcium chan-
nel blockers and nitric acid donors were insufficient to
provide good evidence
New authors helped update this review
1 October 2009 Amended Search updated: 19 reports added to Studies awaiting
classification
3 November 2008 Amended Converted to new review format
31 March 2004 New search has been performed One new trial added to studies awaiting classification
(Hollard 2003)
30 September 2003 New citation required and conclusions have changed With inclusion of Bujold 2003a and Bujold 2003b,
we have changed the recommendation regarding ni-
troglycerine
30 September 2003 New search has been performed Search updated. 2 new trials included (Bujold 2003a;
Bujold 2003b)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have allocated all outcomes to be primary or secondary outcomes. We have included further interventions examined in recent trials
in addition to those originally prespecified in the protocol. We have added an outcome - cephalic vaginal birth not achieved (caesarean
section + vaginal breech births) - to enhance consistency with the findings of other related reviews. Additional outcomes are reported
that were not specified in the protocol: vaginal breech birth, Apgar less than seven at five minutes, neonatal seizures, admission to
neonatal unit, birth trauma, flushing in women, placental abruption, maternal discomfort, pain scores, maternal satisfaction with the
procedure and maternal side effects (nausea and vomiting, dizziness and drowsiness).
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